WO2011072218A2 - Formulations stables pour particules thérapeutiques de lyophilisation - Google Patents

Formulations stables pour particules thérapeutiques de lyophilisation Download PDF

Info

Publication number
WO2011072218A2
WO2011072218A2 PCT/US2010/059879 US2010059879W WO2011072218A2 WO 2011072218 A2 WO2011072218 A2 WO 2011072218A2 US 2010059879 W US2010059879 W US 2010059879W WO 2011072218 A2 WO2011072218 A2 WO 2011072218A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
cyclodextrin
composition
lyophilized
lyophilized pharmaceutical
Prior art date
Application number
PCT/US2010/059879
Other languages
English (en)
Other versions
WO2011072218A3 (fr
Inventor
Greg Troiano
Stephen E. Zale
James Wright
Tina Van Geen Uoven
Young-Ho Song
Original Assignee
Bind Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bind Biosciences filed Critical Bind Biosciences
Priority to CA2783535A priority Critical patent/CA2783535C/fr
Priority to BR112012016021A priority patent/BR112012016021A8/pt
Priority to CN201080061714.3A priority patent/CN102811743B/zh
Priority to EP10836748.3A priority patent/EP2509634B1/fr
Priority to DK10836748.3T priority patent/DK2509634T3/en
Priority to JP2012543308A priority patent/JP5891175B2/ja
Priority to EA201290482A priority patent/EA036522B1/ru
Priority to ES10836748T priority patent/ES2721898T3/es
Publication of WO2011072218A2 publication Critical patent/WO2011072218A2/fr
Publication of WO2011072218A3 publication Critical patent/WO2011072218A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Definitions

  • therapeutics that include an active drug and that are, e.g., targeted to a particular tissue or cell type or targeted to a specific diseased tissue but not to normal tissue, may reduce the amount of the drug in body tissues that do not require treatment. This is particularly important when treating a condition such as cancer where it is desirable that a cytotoxic dose of the drug is delivered to cancer cells without killing the surrounding non-cancerous tissue. Further, such therapeutics may reduce the undesirable and sometimes life- threatening side effects common in anticancer therapy. In addition, such therapeutics may allow drugs to reach certain tissues they would otherwise be unable to reach.
  • nanoparticles Delivery of therapeutic nanoparticles can be achieved through parenteral injection of a reconstituted suspension of the nanoparticles.
  • the original nanoparticle suspension is lyophilized, i.e., freeze dried, for storage before reconstitution. Freeze drying a nanoparticle suspension potentially creates a product for reconstitution with far superior storage stability than its frozen suspension counterpart. Further, freeze drying may provide easier storage that may not require constant, very low, temperatures.
  • the reconstituted lyophilisate must possess physicochemical and performance attributes that are comparable or superior to the original suspension. Redispersing into particles of the same size without trace particulates due to micro-aggregation or undispersed particles is the most challenging aspect of nanoparticle suspension lyophilization.
  • the invention provides a lyophilized pharmaceutical composition comprising polymeric nanoparticles, wherein upon reconstitution of the lyophilized pharmaceutical composition, in less than or about 100 mL of an aqueous medium, the reconstituted composition suitable for parenteral administration comprises: less than 6000 microparticles of greater than or equal to 10 microns; and less than 600 microparticles of greater than or equal to 25 microns. In one embodiment, the reconstituted composition comprises less than 3000 microparticles of greater than or equal to 10 microns; and less than 300 microparticles of greater than or equal to 25 microns. In some embodiment, the reconstituted composition suitable for parenteral administration comprises: less than 6000 microparticles of greater than or equal to 10 microns; and less than 600 microparticles of greater than or equal to 25 microns. In one embodiment, the reconstituted composition comprises less than 3000 microparticles of greater than or equal to 10 microns; and less than 300 microparticles of greater than or equal to 25 microns. In
  • the nanoparticle concentration is about 50 mg/mL.
  • the number of microparticles can be determined by means such as the USP 32 ⁇ 788> by light obscuration particle count test, the USP 32 ⁇ 788> by microscopic particle count test, laser diffraction, and/or single particle optical sensing.
  • the nanoparticles may include an active agent or therapeutic agent, e.g., taxane, and one, two, or three biocompatible polymers.
  • an active agent or therapeutic agent e.g., taxane
  • a therapeutic nanoparticle comprising about 0.2 to about 35 weight percent of a therapeutic agent; about 10 to about 99 weight percent poly(lactic) acid-b/ocfc-poly(ethylene)glycol copolymer or poly(lactic)-co-poly(glycolic) acid-b/ocfc-poly(ethylene)glycol copolymer; and about 0 to about 50 weight percent poly(lactic) acid or poly(lactic) acid-co-poly(glycolic) acid.
  • Exemplary therapeutic agents include antineoplastic agents such as taxanes, e.g., docetaxel and may include about 10 to about 30 weight percent of a therapeutic agent, e.g., a taxane agent.
  • the poly(lactic) acid portion of the copolymer may have a weight average molecular weight of about 16 kDa and the poly(ethylene)glycol portion of the copolymer may have a weight average molecular weight of about 5 kDa.
  • Contemplated lyophilized pharmaceutical compositions may further comprise a sugar, e.g. a disaccharide, monosaccharide or polysaccharide, and an ionic halide salt.
  • a disaccharide can be, for example, sucrose or trehalose, or a mixture thereof.
  • the ionic halide salt may be selected from sodium chloride, calcium chloride, and zinc chloride, or mixtures thereof.
  • the lyophilized pharmaceutical composition may also further comprise a cyclodextrin.
  • the lyophilized pharmaceutical composition may further comprise a sugar such as a disaccharide, an ionic halide salt, and a cyclodextrin.
  • the lyophilized pharmaceutical composition may further comprise a disaccharide and a cyclodextrin, and without the ionic halide salt.
  • the cyclodextrin may be selected from a-cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, or mixtures thereof.
  • the reconstituted composition may have minimal aggregation compared to a reconstituted composition that does not contain an ionic halide salt and/or cyclodextrin.
  • the reconstituted composition may have a polydispersity index of less than 0.2.
  • the nanoparticles have a concentration of about 10-100 mg/mL, e.g. 40-60 mg/mL, or about 50mg/mL.
  • the disclosure provides a pharmaceutical composition suitable for parenteral use upon reconstitution, comprising a plurality of therapeutic particles each comprising a copolymer having a hydrophobic polymer segment and a hydrophilic polymer segment; an active agent; a disaccharide; and an ionic halide salt and/or a cyclodextrin such as a beta-cyclodextrin (e.g. hydroxypropylcyclodextrin (HPbCD).
  • the pharmaceutical composition may further comprise a cyclodextrin.
  • the disclosure provides a pharmaceutical composition suitable for parenteral use upon reconstitution, comprising a plurality of therapeutic particles each comprising a copolymer having a hydrophobic polymer segment and a hydrophilic polymer segment; an active agent; a disaccharide; and a cyclodextrin.
  • the ionic halide salt may be selected from the group consisting of sodium chloride, calcium chloride, and zinc chloride, or mixtures thereof.
  • the cyclodextrin may be selected from a-cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, or mixtures thereof.
  • the copolymer may be poly(lactic) acid-b/ocfc-poly(ethylene)glycol copolymer.
  • a 100 mL aqueous sample may comprise less than 6000 particles having a size greater than or equal to 10 microns; and less than 600 particles having a size greater than or equal to 25 microns.
  • the invention provides a pharmaceutically acceptable formulation for parenteral administration, prepared by a process comprising: a) providing a composition comprising a plurality of therapeutic particles each comprising a copolymer having a hydrophobic polymer segment and a hydrophilic polymer segment; and an active agent;
  • the formulation may further comprise a cyclodextrin.
  • the invention provides a pharmaceutically acceptable formulation for parenteral administration, prepared by a process comprising:
  • composition comprising a plurality of therapeutic particles each comprising a copolymer having a hydrophobic polymer segment and a hydrophilic polymer segment; and an active agent;
  • the lyophilized composition may have a therapeutic particle concentration of greater than about 40 mg/mL.
  • the formulation suitable for parenteral administration may have less than about 600 particles having a size greater than 10 microns in a 10 mL dose.
  • the step of adding a disaccharide and/or an ionic halide salt may comprise adding about 5 to about 15 weight percent sucrose or about 5 to about 20 weight percent (e.g. about 10 to about 20 weight percent) trehalose and about 10 to about 500 mM ionic halide salt.
  • the step may further comprise adding about 1 to about 25 weight percent cyclodextrin.
  • the step of adding a disaccharide and a cyclodextrin may comprise adding about 5 to about 15 weight percent sucrose or about 10 to about 20 weight percent trehalose and about 1 to about 25 weight percent cyclodextrin.
  • the step of lyophilizing may comprise freezing the composition at a temperature of greater than about -40 °C, or a temperature of less than -30 °C, e.g. about - 40 °C to about -30 °C, or about -40 °C to about -25 °C forming a frozen composition; and drying the frozen composition via, e.g., sublimation, to form the lyophilized composition.
  • the disclosure provides a method of preventing substantial aggregation of particles in a pharmaceutical nanoparticle composition comprising adding a sugar and a salt to the lyophilized formulation to prevent aggregation of the nanoparticles upon reconstitution.
  • cyclodextrin is also added to the lyophilized formulation.
  • the disclosure provides a method of preventing substantial aggregation of particles in a reconstituted pharmaceutical nanoparticle composition comprising adding a sugar and a cyclodextrin to a lyophilized formulation comprising nanoparticles; reconstituting the lyophilized formulation, wherein the reconstituted composition does not have substantial aggregation of the nanoparticles.
  • a method of preventing substantial aggregation of particles in a pharmaceutical nanoparticle composition comprising adding a sugar and a cyclodextrin to the lyophilized formulation to prevent aggregation of the nanoparticles upon reconstitution.
  • Figure 1 is a flow chart for an emulsion process for forming disclosed nanoparticles.
  • Figure 2 is a flow diagram for a disclosed emulsion process.
  • Figure 3 depicts the effect of salt concentration and sucrose on particle size in reconstituted nanoparticle suspensions.
  • Figure 4 depicts temperature cycling for various lypholization formulations.
  • Figure 5 depicts the sizes via dynamic light scattering (DLS) of the various reconstituted nanoparticle suspensions disclosed herein.
  • Figure 6 depicts the particulate counts of the various reconstituted nanoparticle suspensions disclosed herein
  • Figure 7 depicts temperature cycling for various lypholization formulations.
  • Figure 8 depicts nanoparticle sizes (measured using DLS) of the various reconstituted nanoparticle suspensions disclosed herein.
  • Figure 9 depicts the particulate counts of the various reconstituted nanoparticle suspensions disclosed herein.
  • Figure 10 depicts the particulate counts of the various reconstituted nanoparticle suspensions disclosed herein.
  • Figure 11 depicts the particulate counts of the various reconstituted nanoparticle suspensions disclosed herein.
  • Figure 12 depicts in vitro release of docetaxel of various nanoparticle suspensions disclosed herein.
  • Figure 13 depicts a differential scanning calorimetry (DSC) measurement of nanoparticle suspensions having 5% trehalose and 10% hydroxypropylcyclodextrin.
  • Figure 14 depicts the DSC properties of nanoparticle suspensions having
  • Figure 15 depicts the DSC properties of nanoparticle suspensions having 20% trehalose and 15% hydroxypropylcyclodextrin.
  • Figure 16 depicts the DSC properties of nanoparticle suspensions having
  • the present invention generally relates to lyophilized polymeric nanoparticle compositions, and methods of making and using such therapeutic compositions.
  • Such compositions may be reconstituted from a lyophilized composition, and may include minimal large aggregations of nanoparticles and/or other materials. Disclosed compositions therefore may be suitable for parenteral use.
  • compositions may include nanoparticles that include an active agent.
  • nanoparticle refers to any particle having a diameter of less than 1000 nm, e.g., about 10 nm to about 200 nm.
  • Disclosed therapeutic nanoparticles may include nanoparticles having a diameter of about 60 nm to about 120 nm, or about 70 nm to about 130 nm, or about 60 nm to about 140 nm.
  • Disclosed nanoparticles may include about 0.2 to about 35 weight percent, about 3 to about 40 weight percent, about 5 to about 30 weight percent, 10 to about 30 weight percent, 15 to 25 weight percent, or even about 4 to about 25 weight percent of an active agent, such as an antineoplastic agent, e.g., a taxane agent (for example, docetaxel).
  • an active agent such as an antineoplastic agent, e.g., a taxane agent (for example, docetaxel).
  • Nanoparticles disclosed herein include one, two, three or more biocompatible and/or biodegradable polymers.
  • a contemplated nanoparticle may include about 10 to about 99 weight percent of a one or more block co-polymers that include a biodegradable polymer and polyethylene glycol, and about 0 to about 50 weight percent of a biodegradable homopolymer.
  • Exemplary therapeutic nanoparticles may include about 40 to about 90 weight percent poly(lactic) acid-poly(ethylene)glycol copolymer or about 40 to about 80 weight percent poly(lactic) acid-poly(ethylene)glycol copolymer.
  • Such poly(lactic) acid- block -poly(ethylene)glycol copolymer may include poly(lactic acid) having a number average molecular weight of about 15 to 20 kDa (or for example about 15 to about 100 kDa, e.g., about 15 to about 80 kDa), and poly(ethylene)glycol having a number average molecular weight of about 2 to about 10 kDa, for example, about 4 to about 6 kDa.
  • a disclosed therapeutic nanoparticle may include about 70 to about 95 weight percent PLA-PEG and about 5 to about 25 weight percent docetaxel.
  • a disclosed therapeutic nanoparticle may include about 30 to about 50 weight percent PLA- PEG, about 30 to about 50 weight percent PLA or PLGA, and about 5 to about 25 weight percent docetaxel.
  • Such PLA ((poly)lactic acid) may have a number average molecular weight of about 5 to about 10 kDa.
  • Such PLGA poly lactic -co-glycolic acid
  • disclosed therapeutic nanoparticles may include a targeting ligand, e.g., a low-molecular weight PSMA ligand effective for the treatment of a disease or disorder, such as prostate cancer, in a subject in need thereof.
  • a targeting ligand e.g., a low-molecular weight PSMA ligand effective for the treatment of a disease or disorder, such as prostate cancer, in a subject in need thereof.
  • the low-molecular weight ligand is conjugated to a polymer
  • the nanoparticle comprises a certain ratio of ligand-conjugated polymery, g., PLA-PEG-Ligand) to non-functionalized polymer (e.g., PLA-PEG or PLGA-PEG).
  • the nanoparticle can have an optimized ratio of these two polymers such that an effective amount of ligand is associated with the nanoparticle for treatment of a disease or disorder, such as cancer.
  • disclosed nanoparticles may further comprise about 0.2 to about 10 weight percent PLA-PEG functionalized with a targeting ligand and/or may include about 0.2 to about 10 weight percent poly (lactic) acid -co poly (glycolic) acid block -PEG- functionalized with a targeting ligand.
  • a targeting ligand may be, in some embodiments, covalently bound to the PEG, for example, bound to the PEG via an alkylene linker, e.g., PLA- PEG- alkylene- GL2.
  • a disclosed nanoparticle may include about 0.2 to about 10 mole percent PLA-PEG-GL2 or poly (lactic) acid -co poly (glycolic) acid-PEG-GL2.
  • PLA-PEG-GL2 or PLGA-PEG-GL2 refers to moieties that may include an alkylene linker (e.g., Q-C20, e.g., (CH 2 )5) linking the PEG to GL2.
  • an alkylene linker e.g., Q-C20, e.g., (CH 2 )5
  • a therapeutic nanoparticle may include about 0.2 to about
  • PLA-PEG-GL2 may include poly(lactic) acid with a number average molecular weight of about 10,000 Da to about 20,000 Da and poly(ethylene) glycol with a number average molecular weight of about 4,000 to about 8,000.
  • the nanoparticles of the invention comprise a matrix of polymers and a therapeutic agent.
  • a therapeutic agent and/or targeting moiety i.e., a low-molecular weight PSMA ligand
  • a targeting moiety e.g., ligand
  • covalent association is mediated by a linker.
  • the therapeutic agent can be associated with the surface of, encapsulated within, surrounded by, and/or dispersed throughout the polymeric matrix.
  • the disclosure is directed toward nanoparticles with at least two macromolecules, wherein the first macromolecule comprises a first polymer bound to a low-molecular weight ligand (e.g., targeting moiety); and the second macromolecule comprising a second polymer that is not bound to a targeting moiety.
  • the nanoparticle can optionally include one or more additional, unfunctionalized, polymers.
  • Polymers can be natural or unnatural (synthetic) polymers. Polymers can be homopolymers or copolymers comprising two or more monomers. In terms of sequence, copolymers can be random, block, or comprise a combination of random and block sequences. Typically, polymers in accordance with the present invention are organic polymers. [0047] The term "polymer,” as used herein, is given its ordinary meaning as used in the art, i.e., a molecular structure comprising one or more repeat units (monomers), connected by covalent bonds. The repeat units may all be identical, or in some cases, there may be more than one type of repeat unit present within the polymer.
  • the polymer can be biologically derived, i.e., a biopolymer.
  • Non-limiting examples include peptides or proteins.
  • additional moieties may also be present in the polymer, for example biological moieties such as those described below. If more than one type of repeat unit is present within the polymer, then the polymer is said to be a "copolymer.” It is to be understood that in any embodiment employing a polymer, the polymer being employed may be a copolymer in some cases. The repeating units forming the copolymer may be arranged in any fashion.
  • the repeating units may be arranged in a random order, in an alternating order, or as a block copolymer, i.e., comprising one or more regions each comprising a first repeat unit (e.g., a first block), and one or more regions each comprising a second repeat unit (e.g., a second block), etc.
  • Block copolymers may have two (a diblock copolymer), three (a triblock copolymer), or more numbers of distinct blocks.
  • Disclosed particles can include copolymers, which, in some embodiments, describes two or more polymers (such as those described herein) that have been associated with each other, usually by covalent bonding of the two or more polymers together.
  • a copolymer may comprise a first polymer and a second polymer, which have been conjugated together to form a block copolymer where the first polymer can be a first block of the block copolymer and the second polymer can be a second block of the block copolymer.
  • a block copolymer may, in some cases, contain multiple blocks of polymer, and that a "block copolymer," as used herein, is not limited to only block copolymers having only a single first block and a single second block.
  • a block copolymer may comprise a first block comprising a first polymer, a second block comprising a second polymer, and a third block comprising a third polymer or the first polymer, etc.
  • block copolymers can contain any number of first blocks of a first polymer and second blocks of a second polymer (and in certain cases, third blocks, fourth blocks, etc.).
  • block copolymers can also be formed, in some instances, from other block copolymers.
  • a first block copolymer may be conjugated to another polymer (which may be a homopolymer, a biopolymer, another block copolymer, etc.), to form a new block copolymer containing multiple types of blocks, and/or to other moieties (e.g., to non-polymeric moieties).
  • the polymer e.g., copolymer, e.g., block copolymer
  • the polymer can be amphiphilic, i.e., having a hydrophilic portion and a hydrophobic portion, or a relatively hydrophilic portion and a relatively hydrophobic portion.
  • a hydrophilic polymer can be one generally that attracts water and a hydrophobic polymer can be one that generally repels water.
  • a hydrophilic or a hydrophobic polymer can be identified, for example, by preparing a sample of the polymer and measuring its contact angle with water (typically, the polymer will have a contact angle of less than 60°, while a hydrophobic polymer will have a contact angle of greater than about 60°).
  • the hydrophilicity of two or more polymers may be measured relative to each other, i.e., a first polymer may be more hydrophilic than a second polymer.
  • the first polymer may have a smaller contact angle than the second polymer.
  • a polymer e.g., copolymer, e.g., block
  • the copolymer contemplated herein includes a biocompatible polymer, i.e., the polymer that does not typically induce an adverse response when inserted or injected into a living subject, for example, without significant inflammation and/or acute rejection of the polymer by the immune system, for instance, via a T-cell response.
  • the therapeutic particles contemplated herein can be non-immunogenic.
  • non-immunogenic refers to endogenous growth factor in its native state which normally elicits no, or only minimal levels of, circulating antibodies, T-cells, or reactive immune cells, and which normally does not elicit in the individual an immune response against itself.
  • Biocompatibility typically refers to the acute rejection of material by at least a portion of the immune system, i.e., a nonbiocompatible material implanted into a subject provokes an immune response in the subject that can be severe enough such that the rejection of the material by the immune system cannot be adequately controlled, and often is of a degree such that the material must be removed from the subject.
  • One simple test to determine biocompatibility can be to expose a polymer to cells in vitro; biocompatible polymers are polymers that typically will not result in significant cell death at moderate concentrations, e.g., at concentrations of 50 micrograms/ 10 6 cells.
  • a biocompatible polymer may cause less than about 20% cell death when exposed to cells such as fibroblasts or epithelial cells, even if phagocytosed or otherwise uptaken by such cells.
  • biocompatible polymers include polydioxanone (PDO), polyhydroxyalkanoate, polyhydroxybutyrate, poly(glycerol sebacate), polyglycolide, polylactide, PLGA, polycaprolactone, or copolymers or derivatives including these and/or other polymers.
  • contemplated biocompatible polymers may be biodegradable, i.e., the polymer is able to degrade, chemically and/or biologically, within a physiological environment, such as within the body.
  • biodegradable polymers are those that, when introduced into cells, are broken down by the cellular machinery (biologically degradable) and/or by a chemical process, such as hydrolysis, (chemically degradable) into components that the cells can either reuse or dispose of without significant toxic effect on the cells.
  • the biodegradable polymer and their degradation byproducts can be biocompatible.
  • a contemplated polymer may be one that hydrolyzes
  • the polymer may degrade upon exposure to heat (e.g., at temperatures of about 37°C). Degradation of a polymer may occur at varying rates, depending on the polymer or copolymer used. For example, the half- life of the polymer (the time at which 50% of the polymer can be degraded into monomers and/or other nonpolymeric moieties) may be on the order of days, weeks, months, or years, depending on the polymer.
  • the polymers may be biologically degraded, e.g., by enzymatic activity or cellular machinery, in some cases, for example, through exposure to a lysozyme (e.g., having relatively low pH).
  • the polymers may be broken down into monomers and/or other nonpolymeric moieties that cells can either reuse or dispose of without significant toxic effect on the cells (for example, polylactide may be hydrolyzed to form lactic acid, polyglycolide may be hydrolyzed to form glycolic acid, etc.).
  • polymers may be polyesters, including copolymers comprising lactic acid and glycolic acid units, such as poly(lactic acid-co-glycolic acid) and poly(lactide-co-glycolide), collectively referred to herein as "PLGA”; and homopolymers comprising glycolic acid units, referred to herein as "PGA,” and lactic acid units, such as poly-L-lactic acid, poly-D-lactic acid, poly-D,L-lactic acid, poly-L-lactide, poly-D-lactide, and poly-D,L-lactide, collectively referred to herein as "PLA.”
  • exemplary polyesters include, for example, polyhydroxyacids; PEGylated polymers and copolymers of lactide and glycolide (e.g., PEGylated PLA, PEGylated PGA, PEGylated PLGA, and derivatives thereof.
  • polyesters include, for example, polyanhydr
  • a polymer may be PLGA.
  • PLGA is a biocompatible and biodegradable co-polymer of lactic acid and glycolic acid, and various forms of PLGA can be characterized by the ratio of lactic acid: glycolic acid.
  • Lactic acid can be L-lactic acid, D-lactic acid, or D,L-lactic acid.
  • the degradation rate of PLGA can be adjusted by altering the lactic acid-glycolic acid ratio.
  • PLGA to be used in accordance with the present invention can be characterized by a lactic acid:glycolic acid ratio of approximately 85: 15, approximately 75:25, approximately 60:40, approximately 50:50, approximately 40:60, approximately 25:75, or approximately 15:85.
  • the ratio of lactic acid to glycolic acid monomers in the polymer of the particle may be selected to optimize for various parameters such as water uptake, therapeutic agent release and/or polymer degradation kinetics can be optimized.
  • polymers may be one or more acrylic polymers.
  • acrylic polymers include, for example, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, amino alkyl methacrylate copolymer, poly( acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid polyacrylamide, amino alkyl methacrylate copolymer, glycidyl methacrylate
  • the acrylic polymer may comprise fully-polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups.
  • polymers can be cationic polymers.
  • cationic polymers are able to condense and/or protect negatively charged strands of nucleic acids (e.g. DNA, RNA, or derivatives thereof).
  • Amine-containing polymers such as poly(lysine), polyethylene imine (PEI), and poly(amidoamine) dendrimers are contemplated for use, in some embodiments, in a disclosed particle.
  • polymers can be degradable polyesters bearing cationic side chains. Examples of these polyesters include poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester).
  • Particles disclosed herein may or may not contain PEG.
  • certain embodiments can be directed towards copolymers containing poly(ester-ether)s, e.g., polymers having repeat units joined by ester bonds (e.g., R-C(0)-0-R' bonds) and ether bonds (e.g., R-O-R' bonds).
  • a biodegradable polymer such as a hydrolyzable polymer, containing carboxylic acid groups, may be conjugated with poly(ethylene glycol) repeat units to form a poly(ester-ether).
  • a polymer (e.g., copolymer, e.g., block copolymer) containing poly(ethylene glycol) repeat units can also be referred to as a "PEGylated" polymer.
  • PEG may be terminated and include an end group, for example, when PEG is not conjugated to a ligand.
  • PEG may terminate in a hydroxyl, a methoxy or other alkoxyl group, a methyl or other alkyl group, an aryl group, a carboxylic acid, an amine, an amide, an acetyl group, a guanidino group, or an imidazole.
  • Other contemplated end groups include azide, alkyne, maleimide, aldehyde, hydrazide, hydroxylamine, alkoxyamine, or thiol moieties.
  • PEGylating a polymer for example, by using EDC (l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) and NHS (N-hydroxysuccinimide) to react a polymer to a PEG group terminating in an amine, by ring opening polymerization techniques (ROMP), or the like
  • EDC l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
  • NHS N-hydroxysuccinimide
  • the molecular weight of the polymers can be optimized for effective treatment as disclosed herein.
  • the molecular weight of a polymer may influence particle degradation rate (such as when the molecular weight of a
  • biodegradable polymer can be adjusted), solubility, water uptake, and drug release kinetics.
  • the molecular weight of the polymer can be adjusted such that the particle biodegrades in the subject being treated within a reasonable period of time (ranging from a few hours to 1-2 weeks, 3-4 weeks, 5-6 weeks, 7-8 weeks, etc.).
  • a disclosed particle can for example comprise a diblock copolymer of PEG and PL(G)A, wherein for example, the PEG portion may have a number average molecular weight of about 1,000-20,000, e.g., about 2,000-20,000, e.g., about 2 to about 10,000, and the PL(G)A portion may have a number average molecular weight of about 5,000 to about 20,000, or about 5,000-100,000, e.g., about 20,000-70,000, e.g. , about 15,000-50,000.
  • an exemplary therapeutic nanoparticle that includes about 10 to about 99 weight percent poly(lactic) acid-poly(ethylene)glycol copolymer or poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer, or about 20 to about 80 weight percent, about 40 to about 80 weight percent, or about 30 to about 50 weight percent, or about 70 to about 90 weight percent poly(lactic) acid- poly(ethylene)glycol copolymer or poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer.
  • Exemplary poly(lactic) acid-poly(ethylene)glycol copolymers can include a number average molecular weight of about 15 to about 20 kDa, or about 10 to about 25 kDa of poly(lactic) acid and a number average molecular weight of about 4 to about 6, or about 2 kDa to about 10 kDa of poly(ethylene)glycol.
  • Disclosed nanoparticles may optionally include about 1 to about 50 weight percent poly(lactic) acid or poly(lactic) acid-co-poly (glycolic) acid (which does not include PEG), or may optionally include about 1 to about 50 weight percent, or about 10 to about 50 weight percent or about 30 to about 50 weight percent poly(lactic) acid or poly(lactic) acid- co-poly (glycolic) acid.
  • poly(lactic) or poly(lactic)-co-poly(glycolic) acid may have a number average molecule weight of about 5 to about 15 kDa, or about 5 to about 12 kDa.
  • Exemplary PLA may have a number average molecular weight of about 5 to about 10 kDa.
  • Exemplary PLGA may have a number average molecular weight of about 8 to about 12 kDa.
  • the polymers of the nanoparticles can be conjugated to a lipid.
  • the polymer can be, for example, a lipid-terminated PEG.
  • the lipid portion of the polymer can be used for self assembly with another polymer, facilitating the formation of a nanoparticle.
  • a hydrophilic polymer could be conjugated to a lipid that will self assemble with a hydrophobic polymer.
  • lipids are oils.
  • any oil known in the art can be conjugated to the polymers used in the invention.
  • an oil can comprise one or more fatty acid groups or salts thereof.
  • a fatty acid group can comprise digestible, long chain (e.g. , Cg-Cso), substituted or unsubstituted hydrocarbons.
  • a fatty acid group can be a C 10 -C 2 o fatty acid or salt thereof.
  • a fatty acid group can be a Q5-C 20 fatty acid or salt thereof.
  • a fatty acid can be unsaturated.
  • a fatty acid group can be monounsaturated.
  • a fatty acid group can be
  • a double bond of an unsaturated fatty acid group can be in the cis conformation. In some embodiments, a double bond of an unsaturated fatty acid can be in the trans conformation.
  • a fatty acid group can be one or more of butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, or lignoceric acid.
  • a fatty acid group can be one or more of palmitoleic, oleic, vaccenic, linoleic, alpha-linolenic, gamma-linoleic, arachidonic, gadoleic, arachidonic, eicosapentaenoic, docosahexaenoic, or erucic acid.
  • optional small molecule targeting moieties are bonded, e.g. , covalently bonded, to the lipid component of the nanoparticle.
  • a nanoparticle comprising a therapeutic agent, a polymeric matrix comprising functionalized and non-functionalized polymers, a lipid, and a low-molecular weight PSMA targeting ligand, wherein the targeting ligand is bonded, e.g. , covalently bonded, to the lipid component of the nanoparticle.
  • the lipid component that is bonded to the low-molecular wei ht targeting moiety is of the Formula V:
  • the lipid can be 1,2 distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and salts thereof, e.g., the sodium salt.
  • the invention provides a target- specific nanoparticle comprising a therapeutic agent, a polymeric matrix, DSPE, and a low-molecular weight PSMA targeting ligand, wherein the ligand is bonded, e.g. , covalently bonded, to DSPE.
  • the nanoparticle of the invention may comprise a polymeric matrix comprising PLGA-DSPE-PEG-Ligand.
  • a contemplated nanoparticle may include a ratio of ligand-bound polymer to non-functionalized polymer effective for the treatment of prostate cancer, wherein the hydrophilic, ligand-bound polymer is conjugated to a lipid that will self assemble with the hydrophobic polymer, such that the hydrophobic and hydrophilic polymers that constitute the nanoparticle are not covalently bound.
  • Self-assembly refers to a process of
  • such a method comprises providing a first polymer that is reacted with a lipid, to form a polymer/lipid conjugate.
  • the polymer/lipid conjugate is then reacted with the low-molecular weight ligand to prepare a ligand-bound polymer/lipid conjugate; and mixing the ligand-bound polymer/lipid conjugate with a second, non-functionalized polymer, and the therapeutic agent; such that the nanoparticle is formed.
  • the first polymer is PEG, such that a lipid-terminated PEG is formed.
  • the lipid is of the Formula V, e.g., 2 distearoyl-sn-glycero-3- phosphoethanolamine (DSPE), and salts thereof, e.g., the sodium salt.
  • DSPE distearoyl-sn-glycero-3- phosphoethanolamine
  • the lipid-terminated PEG can then, for example, be mixed with PLGA to form a nanoparticle.
  • nanoparticles may include an optional targeting moiety, i.e., a moiety able to bind to or otherwise associate with a biological entity, for example, a membrane component, a cell surface receptor, prostate specific membrane antigen, or the like.
  • a targeting moiety present on the surface of the particle may allow the particle to become localized at a particular targeting site, for instance, a tumor, a disease site, a tissue, an organ, a type of cell, etc.
  • the nanoparticle may then be "target specific.”
  • the drug or other payload may then, in some cases, be released from the particle and allowed to interact locally with the particular targeting site.
  • the drug or other payload may be released in a controlled release manner from the particle and allowed to interact locally with the particular targeting site (e.g., a tumor).
  • controlled release (and variants of that term) as used herein (e.g., in the context of "controlled-release system") is generally meant to encompass release of a substance (e.g., a drug) at a selected site or otherwise controllable in rate, interval, and/or amount.
  • Controlled release encompasses, but is not necessarily limited to, substantially continuous delivery, patterned delivery (e.g., intermittent delivery over a period of time that is interrupted by regular or irregular time intervals), and delivery of a bolus of a selected substance (e.g., as a predetermined, discrete amount if a substance over a relatively short period of time (e.g., a few seconds or minutes)).
  • patterned delivery e.g., intermittent delivery over a period of time that is interrupted by regular or irregular time intervals
  • a bolus of a selected substance e.g., as a predetermined, discrete amount if a substance over a relatively short period of time (e.g., a few seconds or minutes)
  • a disclosed nanoparticle includes a targeting moiety that is a low-molecular weight ligand, e.g., a low-molecular weight PSMA ligand.
  • a targeting moiety that is a low-molecular weight ligand, e.g., a low-molecular weight PSMA ligand.
  • binding refers to the interaction between a corresponding pair of molecules or portions thereof that exhibit mutual affinity or binding capacity, typically due to specific or non-specific binding or interaction, including, but not limited to, biochemical, physiological, and/or chemical interactions.
  • Biological binding defines a type of interaction that occurs between pairs of molecules including proteins, nucleic acids, glycoproteins, carbohydrates, hormones, or the like.
  • binding partner refers to a molecule that can undergo binding with a particular molecule.
  • Specific binding refers to molecules, such as polynucleotides, that are able to bind to or recognize a binding partner (or a limited number of binding partners) to a substantially higher degree than to other, similar biological entities.
  • the targeting moiety has an affinity (as measured via a disassociation constant) of less than about 1 micromolar, at least about 10 micromolar, or at least about 100 micromolar.
  • a targeting portion may cause the particles to become localized to a tumor (e.g., a solid tumor) a disease site, a tissue, an organ, a type of cell, etc. within the body of a subject, depending on the targeting moiety used.
  • a tumor e.g., a solid tumor
  • a low-molecular weight PSMA ligand may become localized to a solid tumor, e.g., breast or prostate tumors or cancer cells.
  • the subject may be a human or non-human animal.
  • subjects include, but are not limited to, a mammal such as a dog, a cat, a horse, a donkey, a rabbit, a cow, a pig, a sheep, a goat, a rat, a mouse, a guinea pig, a hamster, a primate, a human or the like.
  • a mammal such as a dog, a cat, a horse, a donkey, a rabbit, a cow, a pig, a sheep, a goat, a rat, a mouse, a guinea pig, a hamster, a primate, a human or the like.
  • a targeting moiety may small target prostate cancer tumors, for example a target moiety may be PSMA peptidase inhibitor. These moieties are also referred to herein as "low-molecular weight PSMA ligands.”
  • PSMA prostate specific membrane antigen
  • expression of PSMA is at least 10-fold overexpressed in malignant prostate relative to normal tissue, and the level of PSMA expression is further up-regulated as the disease progresses into metastatic phases (Silver et al. 1997, Clin. Cancer Res., 3:81).
  • the low-molecular weight PSMA ligand is
  • the butyl-amine compound has the advantage of ease of synthesis, especially because of its lack of a benzene ring.
  • a disclosed nanoparticle may include a conjugate represented
  • a disclosed nanoparticle includes a polymeric compound selected from:
  • Ri is selected from the group consisting of H, and a Q-C20 alkyl group optionally substituted with halogen;
  • R 2 is a bond, an ester linkage, or amide linkage
  • R 3 is an Q-Qo alkylene or a bond
  • x is 50 to about 1500, for example about 170 to about 260;
  • y is 0 to about 50, for example y is 0;
  • z is about 30 to about 456, or about 30 to about 200, for example, z is about 80 to about
  • Agents including, for example, therapeutic agents (e.g., anti-cancer agents), diagnostic agents (e.g., contrast agents; radionuclides; and fluorescent, luminescent, and magnetic moieties), prophylactic agents (e.g., vaccines), and/or nutraceutical agents (e.g., vitamins, minerals, etc.) compose part of the disclosed nanoparticles.
  • therapeutic agents e.g., anti-cancer agents
  • diagnostic agents e.g., contrast agents; radionuclides; and fluorescent, luminescent, and magnetic moieties
  • prophylactic agents e.g., vaccines
  • nutraceutical agents e.g., vitamins, minerals, etc.
  • agents to be delivered in accordance with the present invention include, but are not limited to, small molecules (e.g., cytotoxic agents), nucleic acids (e.g.
  • the agent to be delivered is an agent useful in the treatment of cancer (e.g. , prostate cancer).
  • the active agent or drug may be a therapeutic agent (e.g. a chemotherapeutic) such as mTor inhibitors (e.g., sirolimus, temsirolimus, or everolimus), vinca alkaloids (e.g.
  • vinorelbine or vincristine a diterpene derivative
  • a taxane e.g. paclitaxel or its derivatives such as DHA-paclitaxel or PG- paclitaxel, or docetaxel
  • a cardiovascular agent e.g. a diuretic, a vasodilator, angiotensin converting enzyme, a beta blocker, an aldosterone antagonist, or a blood thinner
  • a corticosteroid e.g. a diuretic, a vasodilator, angiotensin converting enzyme, a beta blocker, an aldosterone antagonist, or a blood thinner
  • an antimetabolite or antifolate agent e.g. methotrexate
  • chemotherapeutic agent e.g. epothilone B
  • an alkylating agent e.g.
  • bendamustine or the active agent or drug may be an siRNA.
  • an active or therapeutic agent may (or may not be) conjugated to e.g. a disclosed polymer that forms part of a disclosed nanoparticle, e.g an active agent may be conjugated (e.g. covalently bound, e.g. directly or through a linking moiety) to PLA or PGLA, or a PLA or PLGA portion of a copolymer such as PLA-PEG or PLGA-PEG
  • Another aspect of this disclosure is directed to systems and methods of making disclosed nanoparticles.
  • using two or more different polymers ⁇ e.g., copolymers, e.g., block copolymers) in different ratios and producing particles from the polymers ⁇ e.g., copolymers, e.g., block copolymers), properties of the particles be controlled.
  • one polymer ⁇ e.g., copolymer, e.g., block copolymer may include a low-molecular weight PSMA ligand, while another polymer ⁇ e.g., copolymer, e.g., block copolymer) may be chosen for its biocompatibility and/or its ability to control immunogenicity of the resultant particle.
  • the particles are formed by providing a solution comprising one or more polymers, and contacting the solution with a polymer nonsolvent to produce the particle.
  • the solution may be miscible or immiscible with the polymer nonsolvent.
  • a water-miscible liquid such as acetonitrile may contain the polymers, and particles are formed as the acetonitrile is contacted with water, a polymer nonsolvent, e.g., by pouring the acetonitrile into the water at a controlled rate.
  • the polymer contained within the solution upon contact with the polymer nonsolvent, may then precipitate to form particles such as nanoparticles.
  • Two liquids are said to be “immiscible” or not miscible, with each other when one is not soluble in the other to a level of at least 10% by weight at ambient temperature and pressure.
  • an organic solution ⁇ e.g., dichloromethane, acetonitrile, chloroform, tetrahydrofuran, acetone, formamide,
  • the first solution may be poured into the second solution (at a suitable rate or speed).
  • particles such as nanoparticles may be formed as the first solution contacts the immiscible second liquid, e.g., precipitation of the polymer upon contact causes the polymer to form nanoparticles while the first solution is poured into the second liquid, and in some cases, for example, when the rate of introduction is carefully controlled and kept at a relatively slow rate, nanoparticles may form.
  • the control of such particle formation can be readily optimized by one of ordinary skill in the art using only routine experimentation.
  • a nanoemulsion process such as the process represented in Figures 1 and 2.
  • a therapeutic agent for example, a first polymer (for example, a diblock co-polymer such as PLA-PEG or PLGA-PEG, either of which may be optionally bound to a ligand, e.g., GL2) and an optional second polymer (e.g., (PL(G)A- PEG or PLA), with an organic solution to form a first organic phase.
  • a first phase may include about 5 to about 50% weight solids, e.g about 5 to about 40% solids, or about 10 to about 30% solids.
  • the first organic phase may be combined with a first aqueous solution to form a second phase.
  • the organic solution can include, for example, toluene, methyl ethyl ketone, acetonitrile, tetrahydrofuran, ethyl acetate, isopropyl alcohol, isopropyl acetate, dimethylformamide, methylene chloride, dichloromethane, chloroform, acetone, benzyl alcohol, Tween 80, Span 80,or the like, and combinations thereof.
  • the organic phase may include benzyl alcohol, ethyl acetate, and combinations thereof.
  • the second phase can be between about 1 and 50 weight percent , e.g., about 5-40 weight percent, solids.
  • the aqueous solution can be water, optionally in combination with one or more of sodium cholate, ethyl acetate, polyvinyl acetate and benzyl alcohol.
  • the oil or organic phase may use solvent that is only partially miscible with the nonsolvent (water). Therefore, when mixed at a low enough ratio and/or when using water pre-saturated with the organic solvents, the oil phase remains liquid.
  • the oil phase may be emulsified into an aqueous solution and, as liquid droplets, sheared into nanoparticles using, for example, high energy dispersion systems, such as homogenizers or sonicators.
  • the aqueous portion of the emulsion, otherwise known as the "water phase” may be a surfactant solution consisting of sodium cholate and pre-saturated with ethyl acetate and benzyl alcohol.
  • Emulsifying the second phase to form an emulsion phase may be performed in one or two emulsification steps.
  • a primary emulsion may be prepared, and then emulsified to form a fine emulsion.
  • the primary emulsion can be formed, for example, using simple mixing, a high pressure homogenizer, probe sonicator, stir bar, or a rotor stator homogenizer.
  • the primary emulsion may be formed into a fine emulsion through the use of e.g., probe sonicator or a high pressure homogenize ⁇ e.g., by using 1, 2, 3 or more passes through a homogenizer.
  • the pressure used may be about 1000 to about 8000 psi, about 2000 to about 4000 psi4000 to about 8000 psi, or about 4000 to about 5000 psi, e.g., about 2000, 2500, 4000 or 5000 psi.
  • Either solvent evaporation or dilution may be needed to complete the extraction of the solvent and solidify the particles.
  • a solvent dilution via aqueous quench may be used.
  • the emulsion can be diluted into cold water to a concentration sufficient to dissolve all of the organic solvent to form a quenched phase.
  • Quenching may be performed at least partially at a temperature of about 5 °C or less.
  • water used in the quenching may be at a temperature that is less that room temperature (e.g., about 0 to about 10°C, or about 0 to about 5 °C).
  • not all of the therapeutic agent e.g., docetaxel
  • a drug solubilizer is added to the quenched phase to form a solubilized phase.
  • the drug solubilizer may be for example, Tween 80, Tween 20, polyvinyl pyrrolidone, cyclodextran, sodium dodecyl sulfate, or sodium cholate.
  • Tween-80 may added to the quenched nanoparticle suspension to solubilize the free drug and prevent the formation of drug crystals.
  • a ratio of drug solubilizer to therapeutic agent e.g., docetaxel
  • a ratio of drug solubilizer to therapeutic agent is about 100: 1 to about 10: 1.
  • the solubilized phase may be filtered to recover the nanoparticles.
  • ultrafiltration membranes may be used to concentrate the nanoparticle suspension and substantially eliminate organic solvent, free drug, and other processing aids (surfactants).
  • Exemplary filtration may be performed using a tangential flow filtration system.
  • a membrane with a pore size suitable to retain nanoparticles while allowing solutes, micelles, and organic solvent to pass nanoparticles can be selectively separated.
  • Exemplary membranes with molecular weight cut-offs of about 300-500 kDa (-5-25 nm) may be used.
  • Diafiltration may be performed using a constant volume approach, meaning the diafiltrate (cold deionized water, e.g., about 0 to about 5°C, or 0 to about 10°C) may added to the feed suspension at the same rate as the filtrate is removed from the suspension.
  • filtering may include a first filtering using a first temperature of about 0 to about 5°C, or 0 to about 10°C, and a second temperature of about 20 to about 30°C, or 15 to about 35°C.
  • filtering may include processing about 1 to about 6 diavolumes at about 0 to about 5°C, and processing at least one diavolume (e.g., about 1 to about 3 or about 1-2 diavolumes) at about 20 to about 30°C.
  • the particles may be passed through one, two or more sterilizing and/or depth filters, for example, using -0.2 ⁇ depth pre-filter.
  • an organic phase is formed composed of a mixture of a therapeutic agent, e.g. , docetaxel, and polymer
  • the organic phase is mixed with an aqueous phase at approximately a 1:5 ratio (oil phase:aqueous phase) where the aqueous phase is composed of a surfactant and some dissolved solvent.
  • the primary emulsion is formed by the combination of the two phases under simple mixing or through the use of a rotor stator homogenizer. The primary emulsion is then formed into a fine emulsion through the use of a high pressure homogenizer. The fine emulsion is then quenched by addition to deionized water under mixing. The quench:emulsion ratio is approximately 8.5: 1.
  • Tween 80 a solution of Tween (e.g., Tween 80) is added to the quench to achieve approximately 2% Tween overall. This serves to dissolve free, unencapsulated drug.
  • Tween 80 a solution of Tween (e.g., Tween 80) is added to the quench to achieve approximately 2% Tween overall. This serves to dissolve free, unencapsulated drug.
  • the nanoparticles are then isolated through either centrifugation or ultrafiltration/diafiltration.
  • nanoparticle and such free therapeutic agent may be e.g., filtered away.
  • about 20 weight percent of active agent (e.g., docetaxel) and about 80 weight percent polymer e.g., the polymer may include about 2.5 mol percent PLA-PEG-GL2 and about 97.5 mol percent PLA-PEG).
  • the polymer may be used in the preparation of a formulation that results in an e.g., final nanoparticle comprising about 10 weight percent active agent (e.g., docetaxel) and about 90 weight percent polymer (where the polymer may include about 1.25 mol percent PLA-PEG-GL2 and about 98.75 mol percent PLA-PEG).
  • Such processes may provide final nanoparticles suitable for administration to a patient that includes about 2 to about 20 percent by weight therapeutic agent, e.g., about 5, about 8, about 10, about 15 percent therapeutic agent by weight.
  • Nanoparticles disclosed herein may be combined with pharmaceutical acceptable carriers to form a pharmaceutical composition, according to another aspect of the invention.
  • the carriers may be chosen based on the route of administration as described below, the location of the target issue, the drug being delivered, the time course of delivery of the drug, etc.
  • compositions of this invention can be administered to a patient by any means known in the art including oral and parenteral routes.
  • patient refers to humans as well as non-humans, including, for example, mammals, birds, reptiles, amphibians, and fish.
  • the non-humans may be mammals (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig).
  • parenteral routes are desirable since they avoid contact with the digestive enzymes that are found in the alimentary canal.
  • inventive compositions may be administered by injection (e.g., intravenous, subcutaneous or intramuscular, intraperitoneal injection), rectally, vaginally, topically (as by powders, creams, ointments, or drops), or by inhalation (as by sprays).
  • injection e.g., intravenous, subcutaneous or intramuscular, intraperitoneal injection
  • rectally rectally, vaginally, topically (as by powders, creams, ointments, or drops), or by inhalation (as by sprays).
  • the nanoparticles of the present invention are administered to a subject in need thereof systemically, e.g., parenterally, or by intravenous infusion or injection.
  • a composition suitable for freezing including nanoparticles disclosed herein and a solution suitable for freezing, e.g., a sugar such as a mono, di, or poly saccharide, e.g. sucrose and/or a trehalose, and/or a salt and/or a cyclodextrin solution is added to the nanoparticle suspension.
  • a sugar such as a mono, di, or poly saccharide, e.g. sucrose and/or a trehalose, and/or a salt and/or a cyclodextrin solution is added to the nanoparticle suspension.
  • the sugar e.g. sucrose or trehalose
  • nanoparticle formulation comprising a plurality of disclosed nanoparticles, sucrose, an ionic halide, and water; wherein the nanoparticles/sucrose/water/ionic halide is about 3-40%/10-40%/20-95%/0.1-10%
  • such solution may include nanoparticles as disclosed herein, about 5% to about 20% by weight sucrose and an ionic halide such as sodium chloride, in a concentration of about 10- 100 mM.
  • a nanoparticle formulation comprising a plurality of disclosed nanoparticles, trehalose, cyclodextrin, and water; wherein the
  • nanoparticles/trehalose/water/cyclodextrin is about 3-40%/1-25%/20-95%/1-25%
  • such solution may include nanoparticles as disclosed herein, about 1% to about 25% by weight trehalose or sucrose (e.g. about 5% to about 25% trehalose or sucrose, e.g. aboutl0% trehalose or sucrose, or about 15% trehalose or sucrose, e.g. about 5% sucrose) by weight)and a cyclodextrin such as ⁇ -cyclodextrin, in a concentration of about 1% to about 25% by weight (e.g. about 5% to about 20%, e.g.
  • Comtemplated formulations may include a plurality of disclosed nanoparticles (e.g. nanoparticles having PLA-PEG and an active agent), and about 2% to about 15 wt% (or about 4% to about 6wt%, e.g. about 5wt%) sucrose and about 5wt% to about 20% (e.g. about 7% wt percent to about 12 wt%, e.g. about 10 wt%) HPbCD).
  • nanoparticles e.g. nanoparticles having PLA-PEG and an active agent
  • about 2% to about 15 wt% or about 4% to about 6wt%, e.g. about 5wt%) sucrose and about 5wt% to about 20% (e.g. about 7% wt percent to about 12 wt%, e.g. about 10 wt%) HPbCD).
  • the present disclosure relates in part to lyophilized pharmaceutical compositions that, when reconstituted, has a minimal amount of large aggregates.
  • Such large aggregates may have a size greater than about 0.5 ⁇ , greater than about 1 ⁇ , or greater than about 10 ⁇ , and can be undesirable in a reconstituted solution.
  • Aggregate sizes can be measured using a variety of techniques including those indicated in the U.S. Pharmacopeia at 32 ⁇ 788>, hereby incorporated by reference.
  • the tests outlined in USP 32 ⁇ 788> include a light obscuration particle count test, microscopic particle count test, laser diffraction, and single particle optical sensing.
  • the particle size in a given sample is measured using laser diffraction and/or single particle optical sensing.
  • the USP 32 ⁇ 788> by light obscuration particle count test sets forth guidelines for sampling particle sizes in a suspension. For solutions with less than or equal to 100 mL, the preparation complies with the test if the average number of particles present does not exceed 6000 per container that are >10 ⁇ and 600 per container that are >25 ⁇ . [0100] As outlined in USP 32 ⁇ 788>, the microscopic particle count test sets forth guidelines for determining particle amounts using a binocular microscope adjusted to 100 + lOx magnification having an ocular micrometer.
  • An ocular micrometer is a circular diameter graticule that consists of a circle divided into quadrants with black reference circles denoting 10 ⁇ and 25 ⁇ when viewed at lOOx magnification.
  • a linear scale is provided below the graticule. The number of particles with reference to 10 ⁇ and 25 ⁇ are visually tallied. For solutions with less than or equal to 100 mL, the preparation complies with the test if the average number of particles present does not exceed 3000 per container that are >10 ⁇ and 300 per container that are >25 ⁇ .
  • a 10 mL aqueous sample of a disclosed composition upon reconstitution comprises less than 600 particles per ml having a size greater than or equal to 10 microns; and/or less than 60 particles per ml having a size greater than or equal to 25 microns.
  • Dynamic light scattering may be used to measure particle size, but it relies on Brownian motion so the technique may not detect some larger particles.
  • Laser diffraction relies on differences in the index of refraction between the particle and the suspension media.
  • the technique is capable of detecting particles at the sub-micron to millimeter range. Relatively small (e.g., about 1-5 weight %) amounts of larger particles can be determined in nanoparticle suspensions.
  • SPOS Single particle optical sensing
  • concentration of the measured sample the weight percentage of aggregates or the aggregate concentration (particles/mL) can be calculated.
  • contemplated disaccharides include kojibiose, nigerose, isomaltose, ⁇ , ⁇ -trehalose, ⁇ , ⁇ - trehalose, sophorose, laminaribiose, gentiobiose, turanose, maltulose, palatinose, gentiobiulose, mannobiase, melibiose, melibiulose, rutinose, rutinulose, and xylobiose.
  • Reconstitution shows equivalent DLS size distributions when compared to the starting suspension. However, laser diffraction can detect particles of > 10 ⁇ in size in some reconstituted solutions.
  • the present invention relates in part to the use of one or more ionic halide salts as an additional lyoprotectant to a sugar, such as sucrose, trehalose or mixtures thereof.
  • Sugars may include disaccharides, monosaccharides, trisaccharides, and/or polysaccharides, and may include other excipients, e.g. glycerol and/or surfactants.
  • a cyclodextrin may be included as an additional lyoprotectant. The cyclodextrin may be added in place of the ionic halide salt. Alternatively, the cyclodextrin may be added in addition to the ionic halide salt.
  • Suitable ionic halide salts may include sodium chloride, calcium chloride, zinc chloride, or mixtures thereof. Additional suitable ionic halide salts include potassium chloride, magnesium chloride, ammonium chloride, sodium bromide, calcium bromide, zinc bromide, potassium bromide, magnesium bromide, ammonium bromide, sodium iodide, calcium iodide, zinc iodide, potassium iodide, magnesium iodide, or ammonium iodide, and/or mixtures thereof. In one embodiment, about 1 to about 15 weight percent sucrose may be used with an ionic halide salt. In one embodiment, the lyophilized pharmaceutical composition may comprise about 10 to about 100 mM sodium chloride. In another embodiment, the lyophilized
  • composition may comprise about 100 to about 500 mM of divalent ionic chloride salt, such as calcium chloride or zinc chloride.
  • the suspension to be lyophilized may further comprise a cyclodextrin, for example, about 1 to about 25 weight percent of cyclodextrin may be used.
  • Suitable cyclodextrin may include a-cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, or mixtures thereof.
  • Exemplary cyclodextrins contemplated for use in the compositions disclosed herein include hydroxypropyl- -cyclodextrin (HPbCD), hydroxyethyl- -cyclodextrin, sulfobutylether- -cyclodextrin, methyl-P-cyclodextrin, dimethyl- ⁇ -cyclodextrin,
  • carboxymethyl-P-cyclodextrin carboxymethyl ethyl - ⁇ -cyclodextrin, diethyl- ⁇ -cyclodextrin, tri-O-alkyl— ⁇ -cyclodextrin, glocosyl- -cyclodextrin, and maltosyl- -cyclodextrin.
  • about 1 to about 25 weight percent trehalose e.g. about 10% to about 15%, e.g. 5 to about 20% by weight
  • the lyophilized pharmaceutical composition may comprise about 1 to about 25 weight percent ⁇ -cyclodextrin.
  • An exemplary composition may comprise nanoparticles comprising PLA-PEG, an
  • active/therapeutic agent about 4% to about 6% (e.g. about 5% wt percent) sucrose, and about 8 to about 12 weight percent (e.g. about 10 wt. %) HPbCD.
  • the invention provides a lyophilized pharmaceutical composition comprising polymeric nanoparticles, wherein upon reconstitution of the lyophilized pharmaceutical composition at a nanoparticle concentration of about 50 mg/mL, in less than or about 100 mL of an aqueous medium, the reconstituted composition suitable for parenteral administration comprises less than 6000, such as less than 3000, microparticles of greater than or equal to 10 microns; and/or less than 600, such as less than 300, microparticles of greater than or equal to 25 microns.
  • the number of microparticles can be determined by means such as the USP 32 ⁇ 788> by light obscuration particle count test, the USP 32 ⁇ 788> by microscopic particle count test, laser diffraction, and single particle optical sensing.
  • the nanoparticles may comprise a poly(lactic) acid-b/ocfc-poly(ethylene)glycol copolymer or poly(lactic)-co-poly(glycolic) acid-b/ocfc-poly(ethylene)glycol copolymer.
  • the poly(lactic) acid portion of the copolymer may have a weight average molecular weight of about 16 kDa and the poly(ethylene)glycol portion of the copolymer may have a weight average molecular weight of about 5 kDa.
  • the reconstituted composition may have minimal aggregation compared to a reconstituted composition that does not contain an ionic halide salt and/or a cyclodextrin.
  • the reconstituted composition may have a polydispersity index of less than 0.2.
  • the invention provides a pharmaceutical composition suitable for parenteral use upon reconstitution, comprising a plurality of therapeutic particles each comprising a copolymer having a hydrophobic polymer segment and a hydrophilic polymer segment; an active agent; a sugar; and an ionic halide salt.
  • the composition may further comprise a cyclodextrin.
  • the ionic halide salt may be selected from the group consisting of sodium chloride, calcium chloride, and zinc chloride, or mixtures thereof.
  • the pharmaceutical composition may comprise about 10 to about 100 mM sodium chloride.
  • the pharmaceutical composition may comprise about 100 to about 500 mM calcium chloride or zinc chloride.
  • the invention provides a pharmaceutical composition suitable for parenteral use upon reconstitution, comprising a plurality of therapeutic particles each comprising a copolymer having a hydrophobic polymer segment and a hydrophilic polymer segment; an active agent; a sugar; and a cyclodextrin.
  • the cyclodextrin may include a-cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, or mixtures thereof.
  • the pharmaceutical composition may comprise about 1 to about 25 weight percent ⁇ -cyclodextrin.
  • the copolymer may be poly(lactic) acid-b/ocfc-poly(ethylene)glycol copolymer.
  • a 100 mL aqueous sample may comprise less than 6000 particles having a size greater than or equal to 10 microns; and less than 600 particles having a size greater than or equal to 25 microns.
  • the invention provides a pharmaceutically acceptable formulation for parenteral administration, prepared by a process comprising: a) providing a composition comprising a plurality of therapeutic particles each comprising a copolymer having a hydrophobic polymer segment and a hydrophilic polymer segment; and an active agent; b) adding a disaccharide and an ionic halide salt to said composition; c) lyophilizing the composition to form a lyophilized composition; d) reconstituting the lyophilized composition to form the formulation suitable for parenteral administration.
  • a cyclodextrin is included in the formulation.
  • such reconstituting can advantageously be managed with simple manual mixing for a few minutes.
  • the reconstituted product attributes e.g. drug purity and/or release profile
  • the invention provides a pharmaceutically acceptable formulation for parenteral administration, prepared by a process comprising: a) providing a composition comprising a plurality of therapeutic particles each comprising a copolymer having a hydrophobic polymer segment and a hydrophilic polymer segment; and an active agent; b) adding a disaccharide and a cyclodextrin to said composition; c) lyophilizing the composition to form a lyophilized composition; d) reconstituting the lyophilized composition to form the formulation suitable for parenteral administration.
  • such reconstituting can advantageously be managed with simple manual mixing for a few minutes.
  • the reconstituted product attributes e.g. drug purity and/or release profile
  • the lyophilized composition may have a therapeutic particle concentration of greater than about 40 mg/mL.
  • the formulation suitable for parenteral administration may have less than about 600 particles having a size greater than 10 microns in a 10 mL dose.
  • the step of adding a disaccharide and an ionic halide salt may comprise adding about 5 to about 15 weight percent sucrose or about 5 to about 20 weight percent trehalose (e.g., about 10 to about 20 weight percent trehalose), and about 10 to about 500 mM ionic halide salt.
  • the ionic halide salt may be selected from sodium chloride, calcium chloride, and zinc chloride, or mixtures thereof. In an embodiment, about 1 to about 25 weight percent cyclodextrin is also added.
  • the step of adding a disaccharide and a cyclodextrin may comprise adding about 5 to about 15 weight percent sucrose or about 5 to about 20 weight percent trehalose (e.g., about 10 to about 20 weight percent trehalose), and about 1 to about 25 weight percent cyclodextrin. In an embodiment, about 10 to about 15 weight percent cyclodextrin is added.
  • the cyclodextrin may be selected from a-cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, or mixtures thereof.
  • the step of lyophilizing may comprise freezing the composition at a temperature of greater than about -40 °C, or e.g. less than about -30 °C, forming a frozen composition; and drying the frozen composition to form the lyophilized composition.
  • the step of drying may occur at about 50 mTorr at a temperature of about -25 to about -34 °C, or about -30 to about -
  • the invention provides a method of preventing substantial aggregation of particles in a pharmaceutical nanoparticle composition comprising adding a sugar and a salt to the lyophilized formulation to prevent aggregation of the nanoparticles upon reconstitution.
  • a cyclodextrin is also added to the lyophilized formulation.
  • the invention provides a method of preventing substantial aggregation of particles in a pharmaceutical nanoparticle composition comprising adding a sugar and a cyclodextrin to the lyophilized formulation to prevent aggregation of the nanoparticles upon reconstitution.
  • EXAMPLE 1 Preparation of PLA-PEG [0124] The synthesis is accomplished by ring opening polymerization of d,l-lactide with a- hydroxy-co-methoxypoly(ethylene glycol) as the macro-initiator, and performed at an elevated temperature using Tin (II) 2-Ethyl hexanoate as a catalyst, as shown below (PEG Mn ⁇ 5,000 Da; PLA Mn ⁇ 16,000 Da; PEG-PLA M n ⁇ 21,000 Da).
  • the polymer is purified by dissolving the polymer in dichloromethane, and precipitating it in a mixture of hexane and diethyl ether. The polymer recovered from this step is dried in an oven.
  • EXAMPLE 2 Exemplary Nanoparticle Preparation - Emulsion Process
  • An organic phase is formed composed of a mixture of docetaxel (DTXL) and polymer (homopolymer, co-polymer, and co-polymer with ligand).
  • the organic phase is mixed with an aqueous phase at approximately a 1:2 ratio (oil phase:aqueous phase) where the aqueous phase is composed of a surfactant (0.25% sodium cholate) and some dissolved solvent (4% ethyl acetate, 2% benzyl alcohol).
  • a surfactant 0.25% sodium cholate
  • solvent 4% ethyl acetate, 2% benzyl alcohol
  • the primary, coarse emulsion is formed by the combination of the two phases under simple mixing or through the use of a rotor stator homogenizer.
  • the rotor/stator yields a homogeneous milky solution, while the stir bar produces a visibly larger coarse emulsion. It is observed that the stir bar method results in significant oil phase droplets adhering to the side of the feed vessel, suggesting that while the coarse emulsion size is not a process parameter critical to quality, it should be made suitably fine in order to prevent yield loss or phase separation. Therefore the rotor stator is used as the standard method of coarse emulsion formation, although a high speed mixer may be suitable at a larger scale.
  • the primary emulsion is then formed into a fine emulsion through the use of a high pressure homogenizer.
  • the size of the coarse emulsion does not significantly affect the particle size after successive passes (103) through the homogenizer.
  • After 2-3 passes the particle size is not significantly reduced, and successive passes can even cause a particle size increase.
  • the organic phase is emulsified 5: 1 0:W with standard aqueous phase, and multiple discreet passes are performed, quenching a small portion of emulsion after each pass.
  • the indicated scale represents the total solids of the formulation.
  • Table A summarizes the emulsification process parameters.
  • the fine emulsion is then quenched by addition to deionized water at a given temperature under mixing.
  • the emulsion is added to a cold aqueous quench under agitation. This serves to extract a significant portion of the oil phase solvents, effectively hardening the nanoparticles for downstream filtration. Chilling the quench significantly improves drug encapsulation.
  • the quench:emulsion ratio is approximately 5: 1.
  • Tween 80 approximately 4% Tween 80 overall After the emulsion is quenched a solution of Tween-80 is added which acts as a drug solubilizer, allowing for effective removal of unencapsulated drug during filtration.
  • Table B indicates each of the quench process parameters.
  • Table B Summary quench process parameters.
  • the temperature must remain cold enough with a dilute enough suspension (low enough concentration of solvents) to remain below the T g of the particles. If the Q:E ratio is not high enough, then the higher concentration of solvent plasticizes the particles and allows for drug leakage. Conversely, colder temperatures allow for high drug encapsulation at low Q:E ratios (to -3: 1), making it possible to run the process more efficiently.
  • nanoparticles are then isolated through a tangential flow filtration process to concentrate the nanoparticle suspension and buffer exchange the solvents, free drug, and drug solubilizer from the quench solution into water.
  • a regenerated cellulose membrane is used with a molecular weight cutoffs (MWCO) of 300.
  • a constant volume diafiltration (DF) is performed to remove the quench solvents, free drug and Tween-80.
  • buffer is added to the retentate vessel at the same rate the filtrate is removed.
  • Crossflow rate refers to the rate of the solution flow through the feed channels and across the membrane. This flow provides the force to sweep away molecules that can foul the membrane and restrict filtrate flow.
  • the transmembrane pressure is the force that drives the permeable molecules through the membrane.
  • the filtered nanoparticle slurry is then thermal cycled to an elevated temperature during workup.
  • a small portion typically 5-10% of the encapsulated drug is released from the nanoparticles very quickly after its first exposure to 25°C.
  • batches that are held cold during the entire workup are susceptible to free drug or drug crystals forming during delivery or any portion of unfrozen storage.
  • This 'loosely encapsulated' drug can be removed and improve the product stability at the expense of a small drop in drug loading.
  • Table D summarizes two examples of 25°C processing. Other experiments have shown that the product is stable enough after -2-4 diavolumes to expose it to 25°C without losing the majority of the encapsulated drug. 5 diavolumes is used as the amount for cold processing prior to the 25°C treatment.
  • Stability data represents the time that final product could be held at 25°C at 10-50 mg/ml nanoparticle concentrations prior to crystals forming in the slurry (visible by microscopy)
  • the nanoparticle suspension is passed through a sterilizing grade filter (0.2 ⁇ absolute).
  • Pre-filters are used to protect the sterilizing grade filter in order to use a reasonable filtration area/ time for the process. Values are as
  • the pre-filter has Seitz PDD 1 depth filter media in Pall SUPRAcap or Stax filter
  • nanoparticle suspensions with >40 mg/mL nanoparticle concentrations are lyophilized in the presence of 10% sucrose and an additive: NaCl, CaCl 2 , or PBS.
  • This experiment formulates nanoparticle suspensions at high (>40 mg/ml) nanoparticle concentrations that can be reconstituted without micro-aggregation. All three CaCl 2 formulations produce reconstituted cakes with ⁇ 100 particles/ml (10 ⁇ +), even in the mid (150 mM) and high (200 mM) concentration ranges which produced a lyophilisate that had collapsed.
  • Nanoparticle suspensions are lyophilized in the presence of a sugar (e.g. sucrose or trehalose), salt (e.g. NaCl or CaCl 2 ), and/or cyclodextrin (e.g. hydroxypropyl beta cyclodextrin - HPbCD).
  • a sugar e.g. sucrose or trehalose
  • salt e.g. NaCl or CaCl 2
  • cyclodextrin e.g. hydroxypropyl beta cyclodextrin - HPbCD
  • formulations are prepared with 250 mM or 500 mM of NaCl or CaCl 2 ; and/or with 15%, 20% or 25% by weight sucrose or trehalose, for example, 20% by weight trehalose, 500mM CaCl 2 , 5% HPbCd. Representative formulations are shown in Table F.
  • Table F indicates particles counted and sized one at a time over a large size range by an AccuSizer, and counted the larger size of particle numbers to find the aggregates that existed in formulation.
  • Table F shows the number of particles after reconstituting solution using distilled water into lyophilized cakes.
  • F/T samples are from freezing and thawing only without drying, whereas vial number from 1 to 4 as well as tall vial 1 and 2 were from lyophilized samples.
  • Most of formulations except CaCl 2 500mM with 15% Trehalose showed low number of particle aggregates and subsequent tests were done to optimize the formulations.
  • Nanoparticle suspensions are lyophilized in the presence of a sugar (e.g. trehalose), cyclodextrin (e.g. hydroxypropyl beta cyclodextrin - HPbCD), and/or salt (e.g. CaCl 2 ).
  • a sugar e.g. trehalose
  • cyclodextrin e.g. hydroxypropyl beta cyclodextrin - HPbCD
  • salt e.g. CaCl 2
  • the excipient and level to screen formulations using Design of Experiment (DOE) are listed below in Table G.
  • Primary drying is performed at -37°C shelf temperature.
  • Cycle data is shown in Figure 4, and shows lyophilization process parameters: shelf temperature, product temperature, chamber pressure and time. These process parameters are controlled from the time the product is first placed on the lyophilizer shelves during loading until the product is removed. Conditions reflected in the chart illustrate the process parameters for one of respective lyo run to screen HPbCD concentration.
  • Nanoparticle suspensions are lyophilized in the presence of a sugar (e.g. trehalose or sucrose) and cyclodextrin (e.g. hydroxypropyl beta cyclodextrin - HPbCD).
  • a sugar e.g. trehalose or sucrose
  • cyclodextrin e.g. hydroxypropyl beta cyclodextrin - HPbCD.
  • the formulations tested are listed below in Table H.
  • Cycle data is shown in Figure 7.
  • the size of the particles in the various lyophilized formulations are measured by dynamic light scattering (DLS) and shown in Figure 8.
  • DLS dynamic light scattering

Abstract

La présente invention concerne, d'une manière générale, des compositions pharmaceutiques lyophilisées qui comprennent des nanoparticules polymères qui, une fois reconstituées, présentent des niveaux faibles de particules de taille supérieure à 10 microns. D'autres aspects de l'invention concernent des méthodes de réalisation de ces nanoparticules.
PCT/US2010/059879 2009-12-11 2010-12-10 Formulations stables pour particules thérapeutiques de lyophilisation WO2011072218A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2783535A CA2783535C (fr) 2009-12-11 2010-12-10 Formulations stables pour particules therapeutiques de lyophilisation
BR112012016021A BR112012016021A8 (pt) 2009-12-11 2010-12-10 Formulações estáveis para liofilização de partículas terapêuticas
CN201080061714.3A CN102811743B (zh) 2009-12-11 2010-12-10 冻干治疗颗粒的稳定制剂
EP10836748.3A EP2509634B1 (fr) 2009-12-11 2010-12-10 Formulations stables pour particules thérapeutiques de lyophilisation
DK10836748.3T DK2509634T3 (en) 2009-12-11 2010-12-10 Stable formulations for lyophilization of therapeutic particles
JP2012543308A JP5891175B2 (ja) 2009-12-11 2010-12-10 治療用粒子の凍結乾燥に対する安定製剤
EA201290482A EA036522B1 (ru) 2009-12-11 2010-12-10 Фармацевтическая композиция, пригодная для лиофилизации, содержащая множество терапевтических частиц
ES10836748T ES2721898T3 (es) 2009-12-11 2010-12-10 Formulaciones estables para liofilizar partículas terapéuticas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28572209P 2009-12-11 2009-12-11
US61/285,722 2009-12-11

Publications (2)

Publication Number Publication Date
WO2011072218A2 true WO2011072218A2 (fr) 2011-06-16
WO2011072218A3 WO2011072218A3 (fr) 2011-10-20

Family

ID=44146202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/059879 WO2011072218A2 (fr) 2009-12-11 2010-12-10 Formulations stables pour particules thérapeutiques de lyophilisation

Country Status (11)

Country Link
US (8) US8357401B2 (fr)
EP (1) EP2509634B1 (fr)
JP (2) JP5891175B2 (fr)
CN (1) CN102811743B (fr)
BR (1) BR112012016021A8 (fr)
CA (1) CA2783535C (fr)
DK (1) DK2509634T3 (fr)
EA (1) EA036522B1 (fr)
ES (1) ES2721898T3 (fr)
TR (1) TR201906255T4 (fr)
WO (1) WO2011072218A2 (fr)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119995A3 (fr) * 2010-03-26 2012-05-03 Cerulean Pharma Inc. Formulations et procédés d'utilisation
US8211473B2 (en) 2009-12-11 2012-07-03 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US8246968B2 (en) 2007-03-30 2012-08-21 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8293276B2 (en) 2008-06-16 2012-10-23 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EP2515942A2 (fr) * 2009-12-15 2012-10-31 Bind Biosciences, Inc. Compositions de nanoparticules polymères à visée thérapeutique à base de copolymères à température de transition vitreuse élevée ou poids moléculaires élevés
WO2013044219A1 (fr) * 2011-09-22 2013-03-28 Bind Biosciences Méthodes de traitement de cancers au moyen de nanoparticules thérapeutiques
WO2013151666A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine
WO2013151736A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Production in vivo de protéines
US8623417B1 (en) 2008-06-16 2014-01-07 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
WO2014009328A1 (fr) * 2012-07-10 2014-01-16 Intervet International B.V. Procédé pour produire un produit médicinal comprenant une protéine biologiquement active et produit ainsi obtenu
US8709483B2 (en) 2006-03-31 2014-04-29 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
EP2777702A1 (fr) * 2013-03-14 2014-09-17 Hikma Pharmaceuticals Formulations pharmaceutiques stabilisées comprenant des composés antinéoplasiques
WO2014152540A1 (fr) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Compositions et procédés de modification des taux de cholestérol
WO2014152211A1 (fr) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
CN104114159A (zh) * 2011-12-14 2014-10-22 阿布拉科斯生物科学有限公司 用于颗粒冻干或冷冻的聚合物赋形剂
US8905997B2 (en) 2008-12-12 2014-12-09 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US8906381B2 (en) 2008-10-12 2014-12-09 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics
WO2015006747A2 (fr) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprenant des polynucléotides synthétiques codant pour des protéines liées à crispr et des arnsg synthétiques et méthodes d'utilisation
WO2015034928A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides chimériques
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
JP2015509529A (ja) * 2012-03-05 2015-03-30 デ スタート デル ネーデルランデン， ヴェルト． ドール デ ミニステル ヴァン ヴイダブリューエス ミニステリー ヴァン ボルクスゲツォントヘイト， ベルジーン エン シュポルトＤｅ Ｓｔａａｔ Ｄｅｒ Ｎｅｄｅｒｌａｎｄｅｎ， Ｖｅｒｔ． Ｄｏｏｒ Ｄｅ Ｍｉｎｉｓｔｅｒ Ｖａｎ Ｖｗｓ Ｍｉｎｉｓｔｅｒｉｅ Ｖａｎ Ｖｏｌｋｓｇｅｚｏｎｄｈｅｉｄ， Ｗｅｌｚｉｊｎ Ｅｎ Ｓｐｏｒｔ 乾燥された生物学的材料を安定化するための方法及び組成物
WO2015075557A2 (fr) 2013-11-22 2015-05-28 Mina Alpha Limited Compositions c/ebp alpha et méthodes d'utilisation
US9198874B2 (en) 2008-12-15 2015-12-01 Bind Therapeutics, Inc. Long circulating nanoparticles for sustained release of therapeutic agents
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2016014846A1 (fr) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Polynucléotides modifiés destinés à la production d'anticorps intracellulaires
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9351933B2 (en) 2008-06-16 2016-05-31 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2017112943A1 (fr) 2015-12-23 2017-06-29 Modernatx, Inc. Procédés d'utilisation de polynucléotides codant pour un ligand ox40
WO2017120612A1 (fr) 2016-01-10 2017-07-13 Modernatx, Inc. Arnm thérapeutiques codant pour des anticorps anti-ctla-4
US9827305B2 (en) 2014-02-17 2017-11-28 Intervet Inc. Poultry virus vaccines that are liquid stable
US9839613B2 (en) 2013-09-27 2017-12-12 Intervet Inc. Dry formulations of vaccines that are room temperature stable
US9855336B2 (en) 2014-02-19 2018-01-02 Intervet Inc. Swine virus vaccines that are liquid stable
US9877923B2 (en) 2012-09-17 2018-01-30 Pfizer Inc. Process for preparing therapeutic nanoparticles
US9895378B2 (en) 2014-03-14 2018-02-20 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
WO2018104538A1 (fr) 2016-12-08 2018-06-14 Curevac Ag Arn pour le traitement ou la prophylaxie d'une maladie du foie
WO2018104540A1 (fr) 2016-12-08 2018-06-14 Curevac Ag Arn pour la cicatrisation des plaies
WO2019048632A1 (fr) 2017-09-08 2019-03-14 Mina Therapeutics Limited Compositions stabilisées de petits arn activateurs (parna) de hnf4a et procédés d'utilisation
WO2019048645A1 (fr) 2017-09-08 2019-03-14 Mina Therapeutics Limited Compositions stabilisées de petits arn activateurs (parna) de cebpa et procédés d'utilisation
WO2019197845A1 (fr) 2018-04-12 2019-10-17 Mina Therapeutics Limited Compositions de sirt1-sarna et procédés d'utilisation
WO2020033791A1 (fr) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations
WO2020208361A1 (fr) 2019-04-12 2020-10-15 Mina Therapeutics Limited Compositions de sirt1-sarna et procédés d'utilisation
WO2021061815A1 (fr) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique du facteur nucléaire hépatocytaire 4-alpha (hnf4α)
WO2021061707A1 (fr) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions et procédés pour moduler l'expression génique de l'apolipoprotéine b (apob)
WO2021183720A1 (fr) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique de forkhead box p3 (foxp3)
WO2022122872A1 (fr) 2020-12-09 2022-06-16 Ucl Business Ltd Agents thérapeutiques pour le traitement des troubles neurodégénératifs
WO2022200810A1 (fr) 2021-03-26 2022-09-29 Mina Therapeutics Limited Compositions de petits arn activateurs de tmem173 et procédés d'utilisation
EP4074834A1 (fr) 2012-11-26 2022-10-19 ModernaTX, Inc. Arn à terminaison modifiée
WO2023283359A2 (fr) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique de la protéine 1 du récepteur frizzled secrété (sfrp1)
WO2023006999A2 (fr) 2021-07-30 2023-02-02 CureVac SE Arnm pour le traitement ou la prophylaxie de maladies hépatiques
EP4144378A1 (fr) 2011-12-16 2023-03-08 ModernaTX, Inc. Nucléoside modifié, nucléotide, et compositions d'acides nucléiques
WO2023099884A1 (fr) 2021-12-01 2023-06-08 Mina Therapeutics Limited Compositions d'arnsa de pax6 et procédés d'utilisation
WO2023104964A1 (fr) 2021-12-09 2023-06-15 Ucl Business Ltd Agents thérapeutiques pour le traitement de troubles neurodégénératifs
WO2023144193A1 (fr) 2022-01-25 2023-08-03 CureVac SE Arnm pour le traitement de la tyrosinémie héréditaire de type i
WO2023161350A1 (fr) 2022-02-24 2023-08-31 Io Biotech Aps Administration nucléotidique d'une thérapie anticancéreuse
WO2023170435A1 (fr) 2022-03-07 2023-09-14 Mina Therapeutics Limited Compositions de petits arn activateurs d'il10 et procédés d'utilisation
US11771707B2 (en) 2016-10-28 2023-10-03 SpineThera Pharmaceutical compositions and uses thereof

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP3578205A1 (fr) 2010-08-06 2019-12-11 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
SG10201807631SA (en) * 2011-01-12 2018-10-30 Intervet Int Bv Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions
EP2691101A2 (fr) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Administration et formulation d'acides nucléiques génétiquement modifiés
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (fr) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Nucleosides, nucleotides et acides nucleiques modifies, et leurs utilisations
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014025890A1 (fr) 2012-08-10 2014-02-13 University Of North Texas Health Science Center Véhicule d'administration de médicament comprenant des conjugués entre des acides polyaminés de ciblage et des acides gras
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
TN2016000137A1 (en) 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016149378A1 (fr) * 2015-03-16 2016-09-22 Pdx Pharmaceuticals, Llc Nanoparticules modifiées par un polymère réticulé
US10436056B2 (en) 2015-06-23 2019-10-08 General Electric Company Relative position measurement
ES2862191T3 (es) * 2015-07-22 2021-10-07 Nitto Denko Corp Composiciones y métodos para formas de liófilos de nanopartículas
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US20180273948A1 (en) * 2015-09-25 2018-09-27 Tarveda Therapeutics, Inc. RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
CA3007955A1 (fr) 2015-12-10 2017-06-15 Modernatx, Inc. Nanoparticules de lipide pour l'administration d'agents therapeutiques
PL3394030T3 (pl) 2015-12-22 2022-04-11 Modernatx, Inc. Związki i kompozycje do wewnątrzkomórkowego dostarczania środków
EP3413918A1 (fr) * 2016-02-10 2018-12-19 Pfizer Inc Nanoparticules thérapeutiques comprenant un agent thérapeutique, et procédés de fabrication et méthodes d'utilisation de ces dernières
JP2019512516A (ja) * 2016-03-25 2019-05-16 ファイザー・インク 治療用粒子を凍結乾燥するための安定した製剤
WO2018089540A1 (fr) 2016-11-08 2018-05-17 Modernatx, Inc. Formulations stabilisées de nanoparticules lipidiques
TWI640328B (zh) * 2017-01-09 2018-11-11 國立成功大學 可供內視鏡治療術應用的即溶乾燥粉末
EP3596042B1 (fr) 2017-03-15 2022-01-12 Modernatx, Inc. Formes cristallines d'aminolipides
HUE060693T2 (hu) 2017-03-15 2023-04-28 Modernatx Inc Vegyület és készítmények terápiás szerek intracelluláris bejuttatására
WO2018232357A1 (fr) 2017-06-15 2018-12-20 Modernatx, Inc. Formulations d'arn
US20200146995A1 (en) * 2017-06-30 2020-05-14 Otomagnetics, Inc. Magnetic nanoparticles for targeted delivery
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
US20210388393A1 (en) * 2018-10-12 2021-12-16 Ann & Robert H. Lurie Children's Hospital of Chicago Plga-peg/pei nanoparticles and methods of use
JP2022548304A (ja) 2019-09-19 2022-11-17 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための分岐状尾部脂質化合物及び組成物
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
MX2022004835A (es) * 2019-10-22 2022-09-09 Otomagnetics Inc Nanopartículas de óxido de hierro recubiertas con lípido para otitis media.
CA3172489A1 (fr) 2020-03-23 2021-09-30 Amit KHANDHAR Compositions de nanoemulsions et methode d'administration d'arn
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
IL310076A (en) * 2021-07-21 2024-03-01 Samyang Holdings Corp A powder formulation for tissue repair, a method for its preparation, and an injectable composition for tissue repair containing it
AU2022352486A1 (en) * 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
KR102640099B1 (ko) * 2022-11-17 2024-02-23 주식회사 삼양홀딩스 조직 수복용 분말 제형 및 이를 포함하는 조직 수복용 주사제 조성물
US11833224B1 (en) 2023-02-08 2023-12-05 Leuvian Llc Lyoprotectant compositions and uses thereof

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394265B1 (fr) 1987-07-29 1994-11-02 The Liposome Company, Inc. Procede de separation granulometrique de particules
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
WO1996020698A2 (fr) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation
WO1996028143A1 (fr) 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Formes galeniques pharmaceutiques contenant un polypeptide, sous forme de microparticules, et leur procede de preparation
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
JP2942508B2 (ja) 1997-01-14 1999-08-30 順也 藤森 温度感受性徐放性基剤及び温度感受性徐放性システム
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP2002519333A (ja) 1998-06-30 2002-07-02 アムジエン・インコーポレーテツド 生物学的に活性な物質の徐放運搬のための感熱性生分解性ヒドロゲル
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
KR100274842B1 (ko) 1998-10-01 2001-03-02 김효근 미립구를 이용한 레티노익산의 서방형 약물방출 시스템
DE19856432A1 (de) 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
CA2321321A1 (fr) 1999-09-30 2001-03-30 Isotis B.V. Polymeres charges d'agents bioactifs
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR100418916B1 (ko) 2000-11-28 2004-02-14 한국과학기술원 생분해성 고분자와 항암제의 접합체를 이용한 서방형미셀제제의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
EP1343480B2 (fr) 2000-12-21 2016-02-17 Alrise Biosystems GmbH Procede comprenant un transition de phase induite pour la production de microparticules contenant des agents actifs hydrophobes
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
EP1345597B1 (fr) 2000-12-27 2007-10-03 Ares Trading S.A. Nanoparticules lipidiques amphiphiles destinees a l'incorporation de peptides et/ou proteines
CA2436408A1 (fr) 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Ligands de la psma modifies et utilisation de ces derniers
AU2002338336A1 (en) 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
AU2002322295C1 (en) 2001-06-21 2008-12-18 Altus Pharmaceuticals Inc. Spherical protein particles and methods of making and using them
US7498045B2 (en) 2001-08-31 2009-03-03 Thomas M. S. Chang Biodegradable polymeric nanocapsules and uses thereof
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
BRPI0213226B1 (pt) 2001-10-10 2016-03-01 Pf Medicament processo de preparação de uma composição farmacêutica sob forma de microesferas com liberação prolongada de um princípio ativo hidrossolúvel, e, microesferas
ES2625340T3 (es) 2001-10-15 2017-07-19 Crititech, Inc. Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20060177495A1 (en) 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
US7408079B2 (en) 2002-01-10 2008-08-05 The Johns Hopkins University Imaging agents and methods of imaging NAALADase or PSMA
AU2003227147A1 (en) 2002-04-05 2003-10-27 Universite De Montreal Stealthy polymeric biodegradable nanospheres and uses thereof
US20030232887A1 (en) 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
AU2003228666A1 (en) 2002-04-23 2003-11-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
JP2003342168A (ja) 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
AU2003293195A1 (en) 2002-12-23 2004-07-29 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US6841547B2 (en) 2003-02-28 2005-01-11 Albert Einstein College Of Medicine Of Yeshevia University Method for decreasing low density lipoprotein
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
JP4989217B2 (ja) 2003-03-26 2012-08-01 エガレット エイ／エス 薬剤物質の送達制御用マトリックス組成物
US20060233883A1 (en) 2003-03-26 2006-10-19 Tsutomu Ishihara Intravenous nanoparticles for targeting drug delivery and sustained drug release
AU2004228008B2 (en) 2003-04-03 2008-11-06 Jessie L.-S. Au Tumor-targeting drug-loaded particles
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
BRPI0412211A (pt) 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
WO2005020989A1 (fr) 2003-09-02 2005-03-10 Novartis Ag Traitement anticancereux utilisant des epothilones
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US7846412B2 (en) 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
AU2005219413A1 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
WO2006002365A2 (fr) 2004-06-24 2006-01-05 Angiotech International Ag Microparticules fortement chargees en agent bioactif
CA2571899A1 (fr) 2004-07-01 2006-08-03 Yale University Materiaux polymeres charges de medicaments cibles a forte densite
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP2006131577A (ja) 2004-11-09 2006-05-25 Ltt Bio-Pharma Co Ltd 異なる粒子径を有する薬物封入ナノ粒子の作製方法および当該方法で得られたナノ粒子
AU2005321543A1 (en) 2004-12-30 2006-07-06 Cinvention Ag Combination comprising an agent providing a signal, an implant material and a drug
WO2006093991A1 (fr) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Composes se liant a l'antigene membranaire specifique de la prostate (psma) et utilisations associees
EP2298318A1 (fr) 2005-04-04 2011-03-23 Sinexus, Inc. Dispositifs et procédés de traitement des affections sinus paranasaux
JP2006321763A (ja) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法
CA2611985C (fr) 2005-06-17 2016-08-16 The University Of North Carolina At Chapel Hill Procedes, systemes et materiaux de fabrication de nanoparticules
PE20100809A1 (es) 2005-07-11 2011-01-07 Wyeth Llc Inhibidores de glutamato de metaloproteinasas de matriz y agrecanasas
NZ623901A (en) * 2005-08-03 2015-10-30 Immunogen Inc Immunoconjugate formulations
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009507049A (ja) 2005-09-09 2009-02-19 北京徳科瑞医薬科技有限公司 リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
CA2623293A1 (fr) 2005-09-20 2007-03-29 Shimon Benita Nanoparticules pour administration ciblee de principes actifs
ES2564241T3 (es) * 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
US8916206B2 (en) 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
WO2007101111A2 (fr) 2006-02-23 2007-09-07 Erimos Pharmaceuticals Llc Méthode de traitement des infections grippales
DE102006013531A1 (de) 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
WO2007133807A2 (fr) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymères pour particules fonctionnelles
SI2049142T2 (sl) * 2006-07-26 2016-04-29 Sandoz Ag Formulacije kaspofungina
CA2659330A1 (fr) 2006-07-31 2008-02-07 Neurosystec Corporation Formulations medicamenteuses nanoparticulaires
US20100144845A1 (en) 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US9248121B2 (en) 2006-08-21 2016-02-02 Abbott Laboratories Medical devices for controlled drug release
WO2008038944A1 (fr) 2006-09-26 2008-04-03 Samyang Corporation Nanoparticule submicronique de dérivés de camptothécine faiblement solubles dans l'eau et son procédé de préparation
CN101778910B (zh) 2006-11-08 2014-05-28 分子制药洞察公司 谷氨酸的异质二聚体
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
CN1957911A (zh) 2006-12-01 2007-05-09 济南康泉医药科技有限公司 一种抗实体肿瘤缓释剂
CN1969818A (zh) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN1969816A (zh) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素的抗癌缓释剂
CN101396340A (zh) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN101433520A (zh) 2006-12-12 2009-05-20 济南帅华医药科技有限公司 含埃坡霉素的抗癌缓释剂
CN101396342A (zh) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 含埃坡霉素衍生物的抗癌缓释注射剂
CN1961864A (zh) 2006-12-12 2007-05-16 济南帅华医药科技有限公司 一种抗癌的组合物
US20100015050A1 (en) 2006-12-21 2010-01-21 Wayne State University Peg and targeting ligands on nanoparticle surface
DK2481409T3 (en) 2007-03-07 2018-08-06 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CN101053553B (zh) 2007-03-16 2011-04-20 吉林大学 一种生物可降解氟尿嘧啶聚酯载药纳米球及其制备方法
EP2136788B1 (fr) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Ciblage de cellules cancéreuses utilisant des nanoparticules
WO2008124634A1 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Micelles inverses encapsulées par un polymère
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
US20100129456A1 (en) 2007-05-14 2010-05-27 Ltt Bio-Pharma Co., Ltd. Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group
EP2187968A4 (fr) 2007-08-21 2013-02-20 Univ Texas Mélange thermocinétique pour des applications pharmaceutiques
US20090061009A1 (en) 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
US20090306120A1 (en) 2007-10-23 2009-12-10 Florencia Lim Terpolymers containing lactide and glycolide
WO2009070302A1 (fr) 2007-11-30 2009-06-04 The Johns Hopkins University Nanoparticules ciblees sur l'antigene membranaire specifique de la prostate (psma) utiles dans le traitement du cancer de la prostate
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
WO2009084801A1 (fr) * 2007-12-31 2009-07-09 Samyang Corporation Composition micellaire de copolymère à blocs amphiphiles contenant du taxane et son procédé de fabrication
EP2106806A1 (fr) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticules pour la livraison ciblée d'agents actifs vers les poumons
EP2285350B1 (fr) 2008-06-16 2017-11-15 Pfizer Inc Procédés pour la préparation de copolymères diblocs fonctionnalisés avec un agent de ciblage destinés à être utilisés dans la fabrication de nanoparticules thérapeutiques
JP2012501966A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005726A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences Inc. Nanoparticules polymères thérapeutiques avec inhibiteurs de mtor et procédés de fabrication et d’utilisation associés
TW201014602A (en) 2008-07-08 2010-04-16 Abbott Lab Prostaglandin E2 binding proteins and uses thereof
US20100058286A1 (en) 2008-08-27 2010-03-04 Vikas Vasudeo Joshi System and a method for rendering computer-based interactions as group activities
WO2010030763A2 (fr) 2008-09-10 2010-03-18 Bind Biosciences, Inc. Fabrication de nanoparticles à rendement élevé
WO2010068866A2 (fr) 2008-12-12 2010-06-17 Bind Biosciences Particules thérapeutiques pour administration parentérale, et procédés de fabrication et d'utilisation associés
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
WO2010114770A1 (fr) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
JP2012522055A (ja) 2009-03-30 2012-09-20 セルリアン・ファーマ・インコーポレイテッド ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法
WO2010114768A1 (fr) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
AU2010254180B2 (en) * 2009-05-27 2015-08-27 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
ES2721898T3 (es) 2009-12-11 2019-08-06 Pfizer Formulaciones estables para liofilizar partículas terapéuticas
EP2512487A4 (fr) 2009-12-15 2013-08-07 Nanoparticules polymères thérapeutiques comprenant de corticostéroïdes, et procédés pour les fabriquer et les utiliser
WO2011084513A2 (fr) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Compositions de nanoparticules polymères à visée thérapeutique à base de copolymères à température de transition vitreuse élevée ou poids moléculaires élevés
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
CN102740895B (zh) 2009-12-23 2016-02-24 伊利诺伊大学董事会 纳米轭合物以及纳米轭合物配制品
WO2011119995A2 (fr) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations et procédés d'utilisation
WO2012040513A1 (fr) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions et procédés d'administration de bêta-lapachone
US20150056300A1 (en) 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
WO2012166923A2 (fr) 2011-05-31 2012-12-06 Bind Biosciences Nanoparticules polymères chargées de médicament et leurs procédés de fabrication et d'utilisation
WO2013044219A1 (fr) 2011-09-22 2013-03-28 Bind Biosciences Méthodes de traitement de cancers au moyen de nanoparticules thérapeutiques
WO2013127490A1 (fr) 2012-02-29 2013-09-06 Merck Patent Gmbh Procédé de fabrication de nanoparticules chargées d'une substance active
NZ705985A (en) 2012-09-17 2018-08-31 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN104812381B (zh) 2012-09-17 2018-01-26 辉瑞大药厂 用于制备治疗性纳米颗粒的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2509634A4 *

Cited By (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US8709483B2 (en) 2006-03-31 2014-04-29 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US8802153B2 (en) 2006-03-31 2014-08-12 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US8246968B2 (en) 2007-03-30 2012-08-21 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9295727B2 (en) 2007-09-28 2016-03-29 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles
US10071056B2 (en) 2007-09-28 2018-09-11 Pfizer Inc. Cancer cell targeting using nanoparticles
US10736848B2 (en) 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
US9539210B2 (en) 2007-10-12 2017-01-10 Massachusetts Institute Of Technology Vaccine nanotechnology
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US11547667B2 (en) 2007-10-12 2023-01-10 Massachusetts Institute Of Technology Vaccine nanotechnology
US9526702B2 (en) 2007-10-12 2016-12-27 Massachusetts Institute Of Technology Vaccine nanotechnology
US8652528B2 (en) 2008-06-16 2014-02-18 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9375481B2 (en) 2008-06-16 2016-06-28 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8623417B1 (en) 2008-06-16 2014-01-07 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US8613954B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8293276B2 (en) 2008-06-16 2012-10-23 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8318208B1 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8663700B2 (en) 2008-06-16 2014-03-04 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8609142B2 (en) 2008-06-16 2013-12-17 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8603534B2 (en) 2008-06-16 2013-12-10 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9351933B2 (en) 2008-06-16 2016-05-31 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8617608B2 (en) 2008-06-16 2013-12-31 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9579284B2 (en) 2008-06-16 2017-02-28 Pfizer Inc. Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US9579386B2 (en) 2008-06-16 2017-02-28 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9393310B2 (en) 2008-06-16 2016-07-19 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8906381B2 (en) 2008-10-12 2014-12-09 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics
US8905997B2 (en) 2008-12-12 2014-12-09 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US9308179B2 (en) 2008-12-15 2016-04-12 Bind Therapeutics, Inc. Long circulating nanoparticles for sustained release of therapeutic agents
US9198874B2 (en) 2008-12-15 2015-12-01 Bind Therapeutics, Inc. Long circulating nanoparticles for sustained release of therapeutic agents
US9872848B2 (en) 2009-12-11 2018-01-23 Pfizer Inc. Stable formulations for lyophilizing therapeutic particles
US8956657B2 (en) 2009-12-11 2015-02-17 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8603535B2 (en) 2009-12-11 2013-12-10 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US9498443B2 (en) 2009-12-11 2016-11-22 Pfizer Inc. Stable formulations for lyophilizing therapeutic particles
US8916203B2 (en) 2009-12-11 2014-12-23 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8637083B2 (en) 2009-12-11 2014-01-28 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8211473B2 (en) 2009-12-11 2012-07-03 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US8912212B2 (en) 2009-12-15 2014-12-16 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US9835572B2 (en) 2009-12-15 2017-12-05 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EP2515942A2 (fr) * 2009-12-15 2012-10-31 Bind Biosciences, Inc. Compositions de nanoparticules polymères à visée thérapeutique à base de copolymères à température de transition vitreuse élevée ou poids moléculaires élevés
US8518963B2 (en) 2009-12-15 2013-08-27 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EP2515942A4 (fr) * 2009-12-15 2013-08-07 Compositions de nanoparticules polymères à visée thérapeutique à base de copolymères à température de transition vitreuse élevée ou poids moléculaires élevés
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011119995A3 (fr) * 2010-03-26 2012-05-03 Cerulean Pharma Inc. Formulations et procédés d'utilisation
WO2013044219A1 (fr) * 2011-09-22 2013-03-28 Bind Biosciences Méthodes de traitement de cancers au moyen de nanoparticules thérapeutiques
JP2015500342A (ja) * 2011-12-14 2015-01-05 アブラクシス バイオサイエンス， エルエルシー 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
CN109771377A (zh) * 2011-12-14 2019-05-21 阿布拉科斯生物科学有限公司 用于颗粒冻干或冷冻的聚合物赋形剂
US10555912B2 (en) 2011-12-14 2020-02-11 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
EP3560486A1 (fr) * 2011-12-14 2019-10-30 Abraxis BioScience, LLC Utilisation d'excipients polymères pour la lyophilisation ou la congélation de particules
AU2017239541B2 (en) * 2011-12-14 2019-07-04 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
AU2012352167B2 (en) * 2011-12-14 2017-07-27 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
US9585960B2 (en) 2011-12-14 2017-03-07 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
KR102203555B1 (ko) * 2011-12-14 2021-01-14 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
CN104114159A (zh) * 2011-12-14 2014-10-22 阿布拉科斯生物科学有限公司 用于颗粒冻干或冷冻的聚合物赋形剂
KR20200029636A (ko) * 2011-12-14 2020-03-18 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
US10076501B2 (en) 2011-12-14 2018-09-18 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
EP2790675A4 (fr) * 2011-12-14 2015-05-06 Abraxis Bioscience Llc Utilisation d'excipients polymères pour la lyophilisation ou la congélation de particules
EP4144378A1 (fr) 2011-12-16 2023-03-08 ModernaTX, Inc. Nucléoside modifié, nucléotide, et compositions d'acides nucléiques
US10335479B2 (en) 2012-03-05 2019-07-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Ministerie Van Volksgezondheid, Welzijn En Sport Methods and compositions for stabilizing dried biological materials
JP2015509529A (ja) * 2012-03-05 2015-03-30 デ スタート デル ネーデルランデン， ヴェルト． ドール デ ミニステル ヴァン ヴイダブリューエス ミニステリー ヴァン ボルクスゲツォントヘイト， ベルジーン エン シュポルトＤｅ Ｓｔａａｔ Ｄｅｒ Ｎｅｄｅｒｌａｎｄｅｎ， Ｖｅｒｔ． Ｄｏｏｒ Ｄｅ Ｍｉｎｉｓｔｅｒ Ｖａｎ Ｖｗｓ Ｍｉｎｉｓｔｅｒｉｅ Ｖａｎ Ｖｏｌｋｓｇｅｚｏｎｄｈｅｉｄ， Ｗｅｌｚｉｊｎ Ｅｎ Ｓｐｏｒｔ 乾燥された生物学的材料を安定化するための方法及び組成物
US9827303B2 (en) 2012-03-05 2017-11-28 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Methods and compositions for stabilizing dried biological materials
WO2013151736A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Production in vivo de protéines
WO2013151666A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine
RU2663581C2 (ru) * 2012-07-10 2018-08-07 Интервет Интернэшнл Б.В. Способ получения лекарственного средства, включающего биологически активный белок, и конечный продукт
WO2014009328A1 (fr) * 2012-07-10 2014-01-16 Intervet International B.V. Procédé pour produire un produit médicinal comprenant une protéine biologiquement active et produit ainsi obtenu
US9526780B2 (en) 2012-08-21 2016-12-27 Intervet Inc. Liquid stable virus vaccines
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9877923B2 (en) 2012-09-17 2018-01-30 Pfizer Inc. Process for preparing therapeutic nanoparticles
EP4074834A1 (fr) 2012-11-26 2022-10-19 ModernaTX, Inc. Arn à terminaison modifiée
US8974811B2 (en) 2013-03-14 2015-03-10 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
US9211336B2 (en) 2013-03-14 2015-12-15 Hikma Pharmaceuticals Antioxidant stabilized pharmaceutical formulations comprising antineoplastic compounds
WO2014152211A1 (fr) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
US9211335B2 (en) 2013-03-14 2015-12-15 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
EP2777702A1 (fr) * 2013-03-14 2014-09-17 Hikma Pharmaceuticals Formulations pharmaceutiques stabilisées comprenant des composés antinéoplasiques
US9603924B2 (en) 2013-03-15 2017-03-28 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
WO2014152540A1 (fr) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Compositions et procédés de modification des taux de cholestérol
WO2015006747A2 (fr) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprenant des polynucléotides synthétiques codant pour des protéines liées à crispr et des arnsg synthétiques et méthodes d'utilisation
EP3971287A1 (fr) 2013-07-11 2022-03-23 ModernaTX, Inc. Compositions comprenant des polynucléotides synthétiques codant pour des protéines liées à crispr et des arnsg synthétiques et méthodes d'utilisation
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015034928A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides chimériques
US9839613B2 (en) 2013-09-27 2017-12-12 Intervet Inc. Dry formulations of vaccines that are room temperature stable
WO2015075557A2 (fr) 2013-11-22 2015-05-28 Mina Alpha Limited Compositions c/ebp alpha et méthodes d'utilisation
EP3985118A1 (fr) 2013-11-22 2022-04-20 MiNA Therapeutics Limited Compositions d'arn à activation courte c/ebp alpha et leurs procédés d'utilisation
EP3594348A1 (fr) 2013-11-22 2020-01-15 Mina Therapeutics Limited Compositions d'arn à activation courte c/ebp alpha et leurs procédés d'utilisation
US9827305B2 (en) 2014-02-17 2017-11-28 Intervet Inc. Poultry virus vaccines that are liquid stable
US9855336B2 (en) 2014-02-19 2018-01-02 Intervet Inc. Swine virus vaccines that are liquid stable
US10071100B2 (en) 2014-03-14 2018-09-11 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
US9895378B2 (en) 2014-03-14 2018-02-20 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
WO2016014846A1 (fr) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Polynucléotides modifiés destinés à la production d'anticorps intracellulaires
WO2017112943A1 (fr) 2015-12-23 2017-06-29 Modernatx, Inc. Procédés d'utilisation de polynucléotides codant pour un ligand ox40
EP4039699A1 (fr) 2015-12-23 2022-08-10 ModernaTX, Inc. Procédés d'utilisation de polynucléotides codant le ligand ox40
WO2017120612A1 (fr) 2016-01-10 2017-07-13 Modernatx, Inc. Arnm thérapeutiques codant pour des anticorps anti-ctla-4
US11771707B2 (en) 2016-10-28 2023-10-03 SpineThera Pharmaceutical compositions and uses thereof
EP3808380A1 (fr) 2016-12-08 2021-04-21 CureVac AG Arn pour le traitement ou la prophylaxie d'une maladie du foie
WO2018104540A1 (fr) 2016-12-08 2018-06-14 Curevac Ag Arn pour la cicatrisation des plaies
WO2018104538A1 (fr) 2016-12-08 2018-06-14 Curevac Ag Arn pour le traitement ou la prophylaxie d'une maladie du foie
EP4183882A1 (fr) 2017-09-08 2023-05-24 MiNA Therapeutics Limited Compositions stabilisées de petits arn activateurs (sarn) de hnf4a et procédés d'utilisation
WO2019048632A1 (fr) 2017-09-08 2019-03-14 Mina Therapeutics Limited Compositions stabilisées de petits arn activateurs (parna) de hnf4a et procédés d'utilisation
WO2019048631A1 (fr) 2017-09-08 2019-03-14 Mina Therapeutics Limited Compositions de petits arn activateurs de hnf4a et procédés d'utilisation
WO2019048645A1 (fr) 2017-09-08 2019-03-14 Mina Therapeutics Limited Compositions stabilisées de petits arn activateurs (parna) de cebpa et procédés d'utilisation
EP4233880A2 (fr) 2017-09-08 2023-08-30 MiNA Therapeutics Limited Compositions de petits arn activateurs de hnf4a et procédés d'utilisation
EP4219715A2 (fr) 2017-09-08 2023-08-02 MiNA Therapeutics Limited Compositions stabilisées de saarn cebpa et procédés d'utilisation
EP4242307A2 (fr) 2018-04-12 2023-09-13 MiNA Therapeutics Limited Compositions
WO2019197845A1 (fr) 2018-04-12 2019-10-17 Mina Therapeutics Limited Compositions de sirt1-sarna et procédés d'utilisation
WO2020033791A1 (fr) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations
WO2020208361A1 (fr) 2019-04-12 2020-10-15 Mina Therapeutics Limited Compositions de sirt1-sarna et procédés d'utilisation
WO2021061707A1 (fr) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions et procédés pour moduler l'expression génique de l'apolipoprotéine b (apob)
WO2021061815A1 (fr) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique du facteur nucléaire hépatocytaire 4-alpha (hnf4α)
WO2021183720A1 (fr) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique de forkhead box p3 (foxp3)
WO2022122872A1 (fr) 2020-12-09 2022-06-16 Ucl Business Ltd Agents thérapeutiques pour le traitement des troubles neurodégénératifs
WO2022200810A1 (fr) 2021-03-26 2022-09-29 Mina Therapeutics Limited Compositions de petits arn activateurs de tmem173 et procédés d'utilisation
WO2023283359A2 (fr) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique de la protéine 1 du récepteur frizzled secrété (sfrp1)
WO2023006999A2 (fr) 2021-07-30 2023-02-02 CureVac SE Arnm pour le traitement ou la prophylaxie de maladies hépatiques
WO2023099884A1 (fr) 2021-12-01 2023-06-08 Mina Therapeutics Limited Compositions d'arnsa de pax6 et procédés d'utilisation
WO2023104964A1 (fr) 2021-12-09 2023-06-15 Ucl Business Ltd Agents thérapeutiques pour le traitement de troubles neurodégénératifs
WO2023144193A1 (fr) 2022-01-25 2023-08-03 CureVac SE Arnm pour le traitement de la tyrosinémie héréditaire de type i
WO2023161350A1 (fr) 2022-02-24 2023-08-31 Io Biotech Aps Administration nucléotidique d'une thérapie anticancéreuse
WO2023170435A1 (fr) 2022-03-07 2023-09-14 Mina Therapeutics Limited Compositions de petits arn activateurs d'il10 et procédés d'utilisation

Also Published As

Publication number Publication date
US20130230568A1 (en) 2013-09-05
US20170189368A1 (en) 2017-07-06
JP2016104764A (ja) 2016-06-09
BR112012016021A8 (pt) 2018-06-12
WO2011072218A3 (fr) 2011-10-20
US20130295191A1 (en) 2013-11-07
US8637083B2 (en) 2014-01-28
US8916203B2 (en) 2014-12-23
CA2783535A1 (fr) 2011-06-16
JP2013513616A (ja) 2013-04-22
EP2509634A4 (fr) 2013-04-24
EA201290482A1 (ru) 2013-01-30
US20150283081A1 (en) 2015-10-08
US8603535B2 (en) 2013-12-10
US8211473B2 (en) 2012-07-03
US20130243863A1 (en) 2013-09-19
BR112012016021A2 (pt) 2018-05-02
US9498443B2 (en) 2016-11-22
US9872848B2 (en) 2018-01-23
JP5891175B2 (ja) 2016-03-22
US8956657B2 (en) 2015-02-17
US20120027820A1 (en) 2012-02-02
DK2509634T3 (en) 2019-04-23
CN102811743B (zh) 2015-11-25
TR201906255T4 (tr) 2019-05-21
EA036522B1 (ru) 2020-11-19
US8357401B2 (en) 2013-01-22
CA2783535C (fr) 2017-11-28
US20110275704A1 (en) 2011-11-10
EP2509634A2 (fr) 2012-10-17
ES2721898T3 (es) 2019-08-06
US20130295183A1 (en) 2013-11-07
JP6159787B2 (ja) 2017-07-05
EP2509634B1 (fr) 2019-03-06
CN102811743A (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
US9872848B2 (en) Stable formulations for lyophilizing therapeutic particles
US9579284B2 (en) Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US9351933B2 (en) Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US20170035694A1 (en) Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
WO2010075072A2 (fr) Longues nanoparticules circulantes pour la libération prolongée d'agents thérapeutiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080061714.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836748

Country of ref document: EP

Kind code of ref document: A1

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836748

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2783535

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012543308

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 5367/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010836748

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201290482

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012016021

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012016021

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120611